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6 Summary 
Summary  
Vaccines are complex multi-component products, in which an interdependent relationship 
among constituents exists: the concomitant inclusion of antigens, adjuvants, and excipients 
is essential to guarantee the efficacy of the final product. The selection of adjuvants and 
formulation criteria is a fundamental aspect, having implications towards efficacy, safety and 
stability of vaccines. In this field, the work was aimed at the design, formulation and 
characterization of novel vaccines suitable for intradermal delivery and able to induce earlier 
onset of immune response as well as more potent and longer lasting immune responses in 
comparison to conventional vaccines. With this purpose two different model antigens were 
used to evaluate the intradermal route as immunological target for vaccination: MenC-
CRM197 glycoconjugate and CRM197 protein (detoxified diphtheria toxin). Moreover 
different adjuvants were tested to potentiate and modulate the immune responses towards a 
desired quality profile. The impact of adjuvant-antigen conjugation on immune response 
against the antigen was investigated in comparison to the adjuvant/antigen co-delivery. For 
the first time, the intradermal delivery was evaluated as route for the administration of a 
MenC-CRM197 glycoconjugate vaccine. LT mutant (LTK63), MPL (TLR4a), Toll like 
receptor 7 agonist (TLR7a), αGalCer analog, Dectin-1 receptor agonist (β-(1-3)glucan 
hexasaccharide) and an oil in water (o/w) emulsion have been chosen to target the skin-
resident antigen-presenting cells and to enhance the immune response against the antigen. 
The in vivo evaluation of such novel formulations provided encouraging results with respect 
to quantity, quality and functionality of the induced immune responses. Notably, the 
intradermal delivery of MenC-CRM197 glycoconjugate showed superiority in term of 
immunogenicity and serum bactericidal titers compared to the intramuscular administration, 
highlighting the power of the intradermal route for glycoconjugate vaccine delivery. 
Moreover, the addition of LTK63, TLR4a, TLR7a, αGalCer analog adjuvants allowed the 
reduction of the number of doses administered and especially LTK63, TLR4a, TLR7a 
adjuvants were able to modulate the quality of the immune response towards a more 
beneficial, for the model antigen used, Th1 response. No adjuvant effect was observed when 
formulations were combined with (β-(1-3) glucan hexasaccharide. When MenC-
CRM197 +TLR4a formulation was intradermally delivered in combination with the o/w 
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emulsion adjuvant no additional improvements in immunogenicity were observed in 
comparison to the single adjuvant effect. The immune system activation was also 
investigated using a protein model antigen (CRM197) intradermally; however no 
improvements in term of immunogenity were observed in comparison to the intramuscular 
administration. This finding has specified the interest in selecting a glycoconjugate antigen 
to exploit the advantages of the intradermal route in terms of immunogenicity. To further 
investigate the role of adjuvant and to ensure codelivery of adjuvant/antigen, the 
conjugations of TLR7a to the glycoconjugate model antigen have been investigated. Two 
different approaches were developed: the conjugation of TLR7a to MenC polysaccharide 
and to CRM197 carrier protein. When the conjugation of TLR7a to CRM197 carrier protein 
was tested in vivo, results clearly showed that conjugation of the TLR7a enhances the anti-
carbohydrate response. This effect was less pronounced than after co-administration of a 
commercial glycoconjugate with a standard dose of TLR7a adsorbed on AlumOH. 
Conjugation of the small immunopotentiator molecule was particularly suited for 
vaccination via intradermal delivery, where insoluble salts of aluminum cannot be used 
because of their reactogenicity. These findings have opened the path to the rational design of 
improved adjuvanted glycoconjugate vaccines for intradermal routes. Regarding the 
conjugation of TLR7a to MenC polysaccharide tested in vivo, the obtained results have 
shown a negative impact of the conjugation to MenC polysaccharide receptor recognition 
and consequently a reduction of the anti-MenC carbohydrate response. In order to 
investigate the potential use of a short β-glucan chain as adjuvant for intradermal vaccination 
toward the CRM197 protein model antigen, in comparison to the previously presented 
glycoconjugate model antigen, the results obtained by the in vitro and in vivo evaluation of 
the β-glucan conjugation to the CRM197 protein were reported. The results have 
demonstrated that receptor activation was significantly impacted by the presentation of the 
glucan conjugated to the protein antigen. Considering that glycoconjugate vaccines are some 
of the safest and most effective vaccines for reducing, even eradicating, infectious diseases, 
the conjugation of well-defined synthetic glucans could represent a useful strategy for 
developing new glycoconjugate vaccines for intradermal delivery, with inherent adjuvant 
properties. The combination of antigens and adjuvants needs to be rationally defined to 
develop stable formulations and to give the safest and most efficient response with respect to 
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the considered pathogen and route of administration. In the present work, formulation 
science has been proposed as a key element of novel vaccine development suitable for 
intradermal delivery. 
 
Riassunto 
I vaccini sono prodotti complessi costituiti da più componenti, nei quali esiste un rapporto di 
interdipendenza tra i costituenti: la concomitante presenza di antigeni, adiuvanti, ed 
eccipienti è essenziale per garantire l'efficacia del prodotto finale. La selezione degli 
adiuvanti e i criteri di formulazione sono un aspetto fondamentale, avendo implicazioni su 
efficacia, sicurezza e stabilità dei vaccini. In questo ambito, il lavoro è stato finalizzato alla 
progettazione, formulazione e caratterizzazione di nuovi vaccini atti alla consegna per via 
intradermica e capaci di indurre uno sviluppo precoce, più intenso e più duraturo della 
risposta immunitaria rispetto ai vaccini convenzionali. Con questo scopo due diversi antigeni 
sono stati utilizzati come modello per valutare la via di somministrazione intradermica per la 
vaccinazione: il glicoconiugato MenC-CRM197 e la proteina CRM197  (tossina difterica 
detossificata). Inoltre diversi adiuvanti sono stati usati per potenziare e modulare le risposte 
immunitarie verso un profilo di qualità desiderata. In aggiunta è stato valutato l'impatto che 
la coniugazione dell’adiuvante all’antigene ha sulla risposta immunitaria contro l'antigene in 
confronto alla semplice miscelazione. La via di immunizzazione intradermica è stata 
valutata, per la prima volta, per la somministrazione del glicoconiugato MenC-CRM197. Per 
dirigere l’antigene verso le cellule APC presenti nella pelle e migliorare la risposta 
immunitaria verso l’antigene, sono stati testati diversi adiuvanti, quali la tossina enterica 
detossificata di Escherichia coli (LTK63), un agonista del recettore Toll Like 4 (TLR4a) il 
monofosfolipide A (MPL), un agonista del recettore Toll like 7 (TLR7a), un analogo 
dell’αGalCer, un agonista del recettore Dectin-1 (β- (1-3) hexasaccharide glucano) e 
l’emulsione olio/acqua (o/w). La valutazione in vivo di tali nuove formulazioni ha fornito 
alcuni risultati incoraggianti riguardanti la quantità e la qualità delle risposte immunitarie 
indotte. In particolare, i risultati immunologici ottenuti hanno dimostrato una netta 
superiorità della via di immunizzazione intradermica rispetto a quella intramuscolare quando 
è utilizzato il glicoconiugato MenC-CRM197. Inoltre, l'aggiunta degli adiuvanti LTK63, 
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TLR4a, TLR7a, l’analogo dell’αGalCer ha consentito la riduzione del numero di dosi 
somministrate e soprattutto le formulazioni adiuvantate con LTK63, TLR4a e TLR7a sono 
state in grado di modulare la qualità della risposta immunitaria verso una più vantaggiosa 
risposta Th1. Nessun effetto adiuvante è stato osservato utilizzando il glucano esasaccarico 
come adiuvante miscelato all’antigene. Il glicoconigato MenC-CRM197 adiuvantato con il 
TLR4a è stato consegnato per via intradermica anche in combinazione con l’emulsione o/w, 
ma non è stato osservato alcun effetto adiuvante aggiuntivo della miscela in confronto 
all’effetto dei singoli immunopotenziatori. In aggiunta è stata valutata l’immunogenicità 
della proteina CRM197 a seguito della consegna intradermica ma non è stato osservato alcun 
miglioramento in termini di immunogenicità in confronto alla somministrazione 
intramuscolare. Questo risultato ha messo in evidenza l'importanza dell’adeguata scelta 
dell’antigene per sfruttare i vantaggi della via di immunizzazione intradermica: un antigene 
glicoconiugato è preferibile ad un antigene proteico. Per meglio definire l’effetto adiuvante e 
garantire la concomitante somministrazione  di antigene e adiuvante, sono stati svilippati e 
studiati due approcci di coniugazione del TLR7a all'antigene modello MenC-CRM197: la 
coniugazione del TLR7a prima al polisaccaride MenC e poi alla proteina CRM197. I risultati 
ottenuti dai tests in vivo del coniugato TLR7a alla proteina CRM197  hanno dimostrato che la 
coniugazione del TLR7a migliora la risposta anti-MenC. L’effetto adiuvante del TLR7a 
coniugato si è rivelato meno pronunciato rispetto alla somministrazione di una dose standard 
di TLR7a adsorbito su AlumOH. Bisogna però sottolineare che il sale di alluminio non può 
essere consegnato per via intradermica, dato la sua reattogenicità, perciò ne risulta che la 
coniugazione del TLR7a alla proteina del glicoconiugato MenC-CRM197 può essere molto 
utile per la vaccinazione intradermica. I risultati ottenuti costituiscono la base per una 
razionale progettazione di vaccini glicoconiugati adiuvantati da somministrare per via 
intradermica. Per quanto riguarda l’approccio di coniugazione del TLR7a al MenC, i risultati 
ottenuti in vivo hanno portato alla luce un impatto negativo della coniugazione sul 
riconoscimento recettoriale del polisaccaride e di conseguenza una riduzione della risposta 
anti-MenC. Il glucano esasaccaridico è stato utilizzato per studiare il suo effetto adiuvante 
quando coniugato ad un antigene proteico a seguito di una somministrazione intradermica. I 
risultati ottenuti dalla sperimentazione in vitro ed in vivo dell’esasaccaride coniugato alla 
proteina CRM197 hanno dimostrato che l'attivazione del recettore Dectin-1 è 
  
 
10 Summary 
significativamente influenzata dalla presenza del glucano. Considerando che i vaccini 
glicoconiugati sono alcuni dei vaccini più sicuri e più efficaci per ridurre e sradicare le 
malattie infettive, la coniugazione di glucani sintetici potrebbe rappresentare una strategia 
utile per lo sviluppo di nuovi vaccini glicoconiugati adatti alla somministrazione 
intradermica, con intrinseche proprietà adiuvanti. La combinazione appropriata di antigeni e 
adiuvanti deve guidare la formulazione di vaccini stabili che forniscano una risposta più 
sicura ed efficace contro il patogeno desiderato mediante la via di somministrazione scelta. 
Nel presente lavoro, la scienza di formulazione è stata proposta come un elemento chiave 
dello sviluppo di nuovi vaccini adatti alla consegna intradermica. 
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Vaccines  
Vaccines represent one of the most important and effective public-health 
interventions to control infectious diseases. Impact of vaccination is clearly proven 
by the eradication of smallpox and the extraordinary reduction of the morbidity and 
mortality due to various diseases in the world (1-2). During the last three centuries 
vaccinology has enabled the development of numerous vaccines, and modern 
approaches appear promising for the selection and the design of novel protective 
antigens that will increase the number of preventable diseases in the future. 
 
 Vaccine formulations 
However vaccine formulations are complex biopharmaceutical products, in which 
the appropriate combination of antigen(s) and adjuvant(s) is a crucial aspect for the 
efficacy and safety. All these active components need to be stable in a wide range 
of storage conditions, so different techniques for vaccine formulation 
characterization are required in order to define their reproducibility and robustness. 
Different regulatory organizations clarify the requirements for vaccine development 
(3-4). The modern approach of vaccine formulation development to transform the 
discovery of an immunogen into a usable vaccine includes: 
- physical and chemical characterization of the antigenic component; 
- development of stability/potency indicating assays;  
- evaluation and optimization of the route of administration and adjuvants 
- appropriate formulation design to maximize the candidate vaccine's stability, 
shelf life, and immunogenic potential.  
In the setup process of vaccine formulations, stabilizers and protectors cover an 
important role for the stability in storage and transportation. In particular, vaccine 
development for developing countries must include consideration of the difficulty 
to ensure the maintenance of cold chain across the entire commercial distribution 
and storage infrastructure. The World Health Organization (WHO) and PATH have 
developed strategies to better implement improvements in vaccine stability and the 
vaccine cold chain worldwide (5-6). Some intradermal delivery devices such as 
microneedle patches are likely to occupy less volume than vials or prefilled 
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syringes, thereby reducing demands on cold-chain capacity. However the 
development of these new devices imply the development of new formulation 
dosages and compositions in order to deliver the same amount of antigen in a 
smaller volume per dose, while maintaining integrity and immunogenicity after 
assembly. The rational selection of vaccine components, route and device of 
delivery allows for choosing the best formulation strategy in order to obtain the 
desired immune response against the target-diseases.  
 
Intradermal immunization 
The skin is the most peripheral tissue that covers all of the body. One of its major 
functions is to protect the interior of the body from pathogens and chemical agents, 
but at the same time acts as a niche for commensal skin flora which is mainly 
composed of bacteria (7). The concept of ‘skin as immunological organ’ was 
launched in the 1980s, describing the prominent presence of immune cells and 
molecules in equilibrium with the systemic immune system (8). The skin is 
composed of three different layers (Figure 2) with specific functions:  
1. epidermis, consisting of stratified squamous epithelium; 
2. dermis, rich of blood capillaries, nerves, lymph vessels, fibroblasts, mast 
cells, macrophages, DCs, Langerhans cells (LCs), natural killer cell and 
natural killer T-cells;   
3. hypodermis, comprising connective tissue, blood vessels, nerve tissue, 
fibroblasts and macrophages (9-11).   
It is important to highlight the fundamental role of skin DCs for the efficacy of 
dermal vaccination, thanks to their essential activity in initiating the immunization, 
with the consequent activation of the immune system (12). The skin is an easily 
accessible organ with optimal connection to the regional lymphatic tissues. In fact, 
after intradermal immunization, besides the targeting of the DCs in the site of 
injection, the vaccine rapidly diffuses into the surrounding tissue and is drained via 
the lymph vessel, reaching the lymph nodes and targeting the lymph nodes resident 
DCs. For these reasons it is possible to deliver vaccines intradermally with superior 
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immune response in comparison to the classical intramuscular routes (12-13) or to 
deliver a smaller quantity of vaccine antigen while obtaining the equivalent immune 
response (14). It is still not known how long the vaccine persists in the site of 
injection after intradermal immunization but viscosity of the injected formulation 
and size of a particle-based vaccine can influence its drainage. To better reach DCs 
and facilitate antigens uptake it is possible to direct the vaccine to specific receptors 
present on the cell surface (15-16). Different C-type lectins, highly expressed, were 
investigated as candidate for antigen targeting to DCs, such as DEC-205, CLEC9A, 
CLEC4A and CLEC12 (16-18).  
 
Figure 2| Skin anatomy. Three different layers compose the skin: epidermis, dermis and 
hypodermis. Age, gender, body mass and body sites influence the hypodermis’s thickness.  (Adapted 
from Lambert PH, Laurent EP. Intradermal vaccine delivery: Will new delivery systems transform 
vaccine administration? Vaccine 2008;26:3197-208)(13). 
Several benefits of intradermal vaccine delivery can be counted, such as dose-
sparing, particularly important in resource-poor settings, by potentially reducing the 
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per-injection cost (including transport and storage) of vaccines because more doses 
might be obtained from the existing vaccine presentation. Dose-sparing might also 
be a solution for the availability of vaccines in cases where supply is limited by 
manufacturing capacity. It is also necessary to ensure adequate immunogenicity 
across the whole target population and potency, of the reduced dose, sufficient to 
induce protection at the end of the vaccine shelf life. The use of needle-free devices, 
such as for example microneedle patches, drives a reduction in the health-care costs 
resulting from self-administration, simplicity of use and small-packaged volumes. 
Moreover the use of needle-free disposable devices allows the reduction of needle 
stick injuries. However, some challenges need to be addressed regarding the 
vaccine manufacture, device development and approval by regulatory authorities 
for intradermal vaccination. For instance, smaller administration volumes are 
typically requested compared to other routes, thereby the antigen might need to be 
concentrated in order to ensure adequate amount of antigen delivery. Moreover, 
without the development of successful methods to coat sufficient antigen onto 
microneedles, or new devices, and controlling the reproducibility of antigen 
delivery, all the upstream research work becomes in vain (19). 
 
Vaccine adjuvants 
The discovery of the immune-enhancing effects of adding an adjuvant to a vaccine 
was an important milestone in the vaccine history. Most of the licensed vaccines are 
based on highly purified recombinant antigens or on subunits of pathogens, which 
significantly decrease the risk of vaccine toxicity but, as a consequence, reduce 
their immunostimulatory activity.  
The importance of combing such antigens with compounds able to potentiate, 
modulate and boost the antigen-specific immune response becomes clear. These 
immunostimulatory molecules are known as adjuvants (from the Latin word 
adiuvare meaning 'to help') (20) and play a key role in modern vaccines.  
Vaccine adjuvants can be classified according to their source (natural, synthetic or 
endogenous), mechanism of action, or physical or chemical properties. However, 
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due to their great diversity, an accurate separation is difficult to achieve. The most 
appropriate existing classification divides adjuvants in two main groups on the basis 
of their main mechanism(s) of action (21). The first considers adjuvants as 
“delivery systems”, according to the key function to target and localize antigens to 
antigen-presenting cells (APCs); the second takes into account the role of adjuvants 
as immunopotentiators. In the latter group molecules able to directly activate the 
cells of the innate immune system through specific receptors, contributing to the 
inflammatory context required for optimal immune responses are included. 
 
 Adjuvants impact on immune mechanisms 
- Help to make antigens more visible or reactive to the immune system 
- Creation of an antigen depot at the injection site 
- Improved antigen delivery and enhanced uptake by APCs 
- Direct activation of innate immune cells, including APCs 
-Mimic natural defensive molecules 
- Release of cytokines and chemokines 
- Potent stimulation of targeted adaptive immune responses 
 
 Expected benefits of adjuvants 
- Stronger immune priming 
- Faster immune response  
- Enhanced immune response 
- Broader and cross-protective immunity 
- Longer lasting immune response, fewer boosters needed 
 
- Enhanced and effective immune responses in specific low-responding 
populations (newborns, elderly, immunocompromised patients) 
 
- Antigen sparing (use of smaller amounts of the antigen) 
- Reduction of costs 
- Face pandemic events 
 
- Overcoming antigenic  competition in complex vaccine combinations 
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 Adjuvants requisites 
- Easy manufacture 
- Stability 
- Acceptable safety  and tolerability profile 
 
 Adjuvants suitable for intradermal immunization 
Various adjuvants have been used for intradermal immunization and their selection 
could be based on whether a Th1 or Th2, or mixed Th1/Th2, immune response is 
preferred. A first group of adjuvants are represented by the bacterial adenosine 
diphosphate (ADP)-ribosylating exotoxins as Cholera toxin (CT), Escherichia coli 
heat labile toxin (LT), or subunits of these proteins have commonly been utilized to 
elicit or enhance the response toward a vaccine given via the cutaneous route (22-
25). It is not yet clear how bacterial ADP-ribosylating toxins influence the type of 
immune reaction but several studies report the induction of Th2-biased immunity 
(22) and CTL proliferation, indicating activation of epidermal LCs (26). A second 
group of adjuvants for intradermal immunization are specific ligands of toll-like 
receptors (TLR). These receptors play a major role in the detection of pathogens 
and are therefore an ideal target for enhancing the immune reaction (27). In table 1 
are reported a wide variety of adjuvants that have been utilized in cutaneous 
vaccination studies (28). A suitable experimental model to investigate immediate 
and long-term skin reactions after intradermal adjuvants injection remains to be 
developed. For example, adverse reactions were observed after aluminum 
hydroxide intradermal injection, in particular the development of persistent 
intradermal granulomas (29). Different studies have evaluated a-
Galactosylceramide (a-GalCer), a synthetic glycolipid, as a potential adjuvant, 
because it selectively and potently activates natural killer T (NKT) cells, which are 
among the most effective innate immune modulators for inducing activation and 
maturation of dendritic cells (DC) that in turn induce CD4 and CD8 T-cell mediated 
adaptive immune responses (30-32). This glycolipid seems to be suitable for 
intradermal vaccination due to the high presence of DCs in the skin layer.    
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Table 1|Overview of adjuvants and their effects on the immune response upon cutaneous 
vaccination compared to non-adjuvanted (w/o) studies. (Adapted from Engelke L, Winter G, Hook 
S, Engert J. Recent insights into cutaneous immunization: How to vaccinate via the skin. Vaccine 
2015;33:4663-74)(28).  
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Immune responses and vaccination 
The deliberate stimulation of an immune response by immunization was originated 
in 1796 with E. Jenner’s experiments, in which the cowpox virus was inoculated 
into the skin to render individuals resistant to the subsequent infection with lethal 
smallpox virus. This practice, called vaccination, takes advantage of the immune 
system’s capacity to develop an adaptive immune response after an exposure to a 
small sample of disease-causing microorganism - or to a part or portion of it (Figure 
1). The main actors of the adaptive immune response are antibodies secreted by B 
lymphocytes. These antibodies can act in different ways to protect against the 
pathogens: they can neutralize the pathogens by blocking their access to the binding 
sites on the host cell surface, a mode of action that is very important for protection 
against viruses; antibodies can coat the bacteria in order to make them attractive for 
phagocytes, which have receptors able to recognize the stems of the antibodies 
coating, also known as opsonization process; antibodies can manage the activation 
of the complement system once they have coated the pathogen surface, with the 
results of lysis and ingestion by phagocytes (33). Other important effectors of 
adaptive immune response are the CD8
+
 cytotoxic T lymphocytes (CTL) that have a 
role in the eradication of viruses and tumors. In effect, immunotherapies that 
promote antitumor CTL responses showed significant evidence of clinical success 
in the melanoma, renal and lung cancers treatments (34). The activation of B-cells 
to produce antibodies, their class switching and affinity is supported by growing 
factors and signals provided by CD4
+ 
T helper cells (Th). The protective efficacy of 
a vaccine is often conferred to the production of antigen-specific antibodies but this 
is not always sufficient. T-cells play an important role in developing an effective 
and long lasting immune response. The antigen-specific T-cell activation is driven 
by the specific antigen presenting cells (APC), of wich the dendritic cells (DC) are 
the most professional. They can perform uptake of microorganisms in different 
ways (phagocytosis, endocytosis and pinocytosis), with the consequent loading on 
MHC class II of processed molecules and secretion of specific cytokines. 
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Figure 1| Induction of adaptive immune responses. Pattern-recognition receptors (PRRs), 
expressed by dendritic cells (DCs), recognize and bind the pathogen-associated molecular patterns 
(PAMPs,) contained in vaccine formulation after the delivery. This connection leads to DC 
activation, maturation and migration to the lymph nodes. The activated DCs present antigens to 
naïve T-cells and stimulate their differentiation by specific cytokines secretion. (Adapted from 
Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in 
vaccination. Nat Rev Immunol. 2012;12:479-49)(35).  
DCs, monocytes and neutrophils constitute the first line of defense against invading 
microbial pathogens and rely on a large family of pattern recognition receptors 
(PRRs), which detect distinct evolutionarily conserved structures on pathogens, 
termed pathogen-associated molecular patterns (PAMPs). The potential to activate 
DCs targeting their surface receptors can be a good strategy to manipulate the first 
line of defense against invading pathogens.   
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Outline of the thesis 
The PhD work was aimed at the design, formulation and characterization of a novel 
vaccine suitable for intradermal delivery and able to induce earlier onset of immune 
response as well as more potent and longer lasting immune responses compared to 
conventional vaccines. In this context adjuvants are used to potentiate the immune 
responses towards specific antigens and to modulate the immune response towards 
a desired quality profile. Conjugation of adjuvants to a model antigen is 
investigated for its potential to increase antigen immune response when compared 
to co-delivery of adjuvant and antigen by simple mixture in respective formulations. 
The thesis reports obtained results through the in vitro and in vivo testing of 
different adjuvants in physical mixture or conjugated to model antigens. 
 
 Chapter 2: Evaluation of receptors agonists as immunopotentiators for 
glycoconjugate vaccines – is focused on the hypothesis that by targeting the 
superficial receptors present on skin-resident antigen-presenting cells, using 
receptor agonists as adjuvants, it is possible to enhance the immune response 
against the model antigen. In particular, were investigated: 
- a small molecule as toll like receptor 7 agonist; 
- Monophosphoryl Lipid A (MPL) as toll like receptor 4 agonist; 
- the heat-labile enterotoxin from Escherichia coli (LT) mutant as GM1 
receptor agonist;  
- a short β-glucan as Dectin-1 (CLEC9A) receptor agonist; 
- a α-GalCer analog as CD-1d receptor agonists; 
The MPL immunopotentiator was also studied in combination with an oil-in-
water emulsion (o/w) adjuvant.  
This work finds its justification in the discovery of novel adjuvants suitable 
for intradermal vaccination since the classical adjuvant, aluminum salt, 
cannot be used for intradermal immunization due its local reactogenicity. 
This work is part of a broader vision of development of new devices for 
intradermal vaccination, such as microneedles patches, in which the 
optimized formulation can elicit an efficient and long lasting immune 
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response. The Meningococcal C glycoconjugate vaccine was used as a 
model antigen for intradermal and intramuscular investigations. 
 
 Chapter 3: The adjuvant effect and impact of conjugation of TLR7 
agonist in a tricomponent anti serogroup C meningococcal 
glycoconjugate vaccine – is focused on the TLR7 agonist adjuvanticity 
investigation after intramuscular delivery; where the TLR7 agonist is either 
co-delivered or conjugated to the Meningococcal C glycoconjugate vaccine. 
Two different approaches of agonist conjugation were investigated in vivo:  
- TLR7a conjugation to CRM197 carrier protein;   
- TLR7a conjugation to MenC polysaccharide; 
The in vitro receptor activation and in vivo immunological evaluations were 
reported. The TLR7a adjuvanticity was compared to the classical aluminum 
salts adjuvant suitable for intramuscular vaccine delivery.  
 
 Chapter 4: Conjugation of a short β-glucan chain, as Dectin-1 agonist, to 
the detoxified diphtheria toxin (𝐂𝐑𝐌𝟏𝟗𝟕) as model antigen, to enhance 
the immune response after intradermal vaccination – describes the 
conjugation of a β-glucan hexasaccharide to the CRM197 model antigen as 
strategy to enhance the immune response toward a protein antigen. 
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Evaluation of receptors agonists as 
immunopotentiators for glycoconjugate vaccines 
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Selection of the model antigen  
The Meningococcal C glycoconjugate was used as a model vaccine for the 
investigation of intradermal vaccine delivery as an alternative to the intramuscular 
route. The recommended vaccination schedule of the licensed group C 
meningococcal vaccines is composed by a first intramuscular dose in infancy 
followed by a boost in the adolescence or a single intramuscular dose at 11 years. 
Therefore, the possible elimination of pain at the injection site and the easier 
administration with the possibility of self-administration might increase the vaccine 
acceptance and the numbers of vaccinated people especially in adolescents, which 
often are reluctant to vaccination.  
 
Neisseria meningitidis: disease and vaccines  
Meningococcal meningitis and sepsis are devastating diseases which still affect 
people with an incidence varying between 0.5 and 1000 cases/100 000 depending 
on the epidemiological areas (36). N. meningitidis is a gram-negative β-
proteobacterium and member of the bacterial family Neisseriaceae (Figure 1) (37). 
There are 13 serogroups of N. meningitidis based on different capsular 
polysaccharide structures, but only six serogroups (A, B, C, W-135, X, and Y) 
cause most life-threatening disease (38). Meningococci of serogroups B, C, Y, and 
W-135 express capsules composed entirely of polysialic acid or sialic acid linked to 
glucose or galactose (39), while the capsule of group A N. meningitidis is composed 
of N-acetyl mannosamine-1-phosphate (39). Complement-dependent bactericidal 
activity is an established correlate of protection against meningococcal disease. 
Studies by Goldschneider and colleagues firmly established the role of Ab in 
protection against invasive meningococcal infection (40). Over the past several 
years, much attention has been focused on the role of membrane proteins in 
complement evasion, in particular the interactions between factor H (FH), an 
inhibitor of the alternative pathway of complement, and meningococcal factor H 
binding protein (41-43). Other meningococcal surface molecules that inhibit the 
alternative pathway include Neisseria surface protein A (NspA) and PorB2, which 
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directly bind to FH. Meningococcal infection is a global but not uniform problem 
occurring as sporadic, hyper-sporadic, and epidemic disease. Disease patterns vary 
widely over time and between geographical areas, age groups, and bacterial 
serogroups. Of the five common serogroups (A, B, C, Y and W135) responsible for 
about 90% of infections caused by N. meningitides, serogroups A, B, and C account 
for most cases of meningococcal disease throughout the world, with serogroups B 
and C responsible for the majority of cases in Europe and the Americas and 
serogroups A and C predominating throughout Asia and Africa (44-46). Israel and 
Sweden are the only countries, other than the United States, that have reported an 
increase in serogroup Y disease (47). 
Figure 1| Neisseria meningitidis. Cross-sectional view of the meningococcal cell membrane. 
(Adapted from Rouphael NG, Stephan DS. Neisseria meningitidis: Biology, Microbiology, and 
Epidemiology. Methods Mol Biol. 2012; 799: 1–20 (48)). 
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Table 1| Licensed Meningococcal conjugate vaccine products with used schedules (Adapted from 
Ali A, Zehra Jafri R, Messonnier N, Tevi-Benissan C, Durrheim D, Eskola J et al. Global practices 
of meningococcal vaccine use and impact on invasive disease. Pathogens and Global Health 
2014;108:11-20 (49)). 
 
 
Different vaccines were developed against the meningococcal A, C, W, and Y 
serogroups, including polysaccharide vaccines and polysaccharide–protein 
conjugate vaccines based on the meningococcal capsule. For serogroup B, vaccine 
development has included protein vaccines based on meningococcal outer 
membrane vesicle (OMV) and, more recently, a range of conserved proteins 
including Factor H Binding Protein (fHBP), Neisseria Adhesin A (nadA), and 
Vaccine Manufacturer Serogroups Protein 
Conjugate 
Licensed schedule 
Menveo
TM
 Novartis Vaccines A, C, Y, W Diphtheria 
cross 
In US, one dose at the age 
of 2 years. 2nd dose 2 
months after 1st dose in 
high-risk children aged 2–5 
years 
Reactive 
material 197 
(CRM197) 
In Europe, approved for use 
from 2 months of age 
Menactra
TM
 Sanofi Pasteur A, C, Y, W Diphtheria 
toxoid 
1st dose in children aged 9–
23 months. 2nd dose after 3 
months in the age 2–55 
years. 
Meningitec
TM
 Neuron Biotech C CRM197 4 doses for children <1 year 
at 2, 4, 6, and 12 months. 
One dose for children over 
12 months, teenagers and 
adults 
Menjugate® Novartis Vaccines C CRM197 Age 2–4 months – 3 doses 
8 weeks apart, 4–11 months 
– 2 doses 8 weeks apart, 
≧12 months – 1 dose 
NeisVac-C
TM
 Baxter Bioscience C Tetanus toxoid Age 2–12 months – 2 doses 
2 months apart. ≥12 months 
– 1 dose 
Menitorix
TM
 GlaxoSmithKline C Tetanus toxoid Age 2–12 months – 3 
doses, 1 month apart. 
Booster from 12 months – 
2 years 
MenAfriVac
TM
 Serum Institute of 
India 
A Tetanus toxoid To be defined 
MenHibrix
TM
 GlaxoSmithKline C & Y Tetanus toxoid Age 2–15 months – four 
doses 
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Neisseria Heparin Binding Antigen (NHba) have been used as vaccine components. 
The major disadvantage of polysaccharide vaccines is their inability to produce 
memory cells leading to poor response to boosters and short duration of protection. 
For this reason Meningococcal conjugate vaccines were introduced in 1999 and 
since then, conjugate quadrivalent (A, C, Y, W) and monovalent MenA and MenC 
vaccines (Table 1) have been licensed in various countries. Conjugate vaccines use 
a carrier protein to present the polysaccharide antigen to the immune system, in a 
manner that induces a T-cell immune response.  
 
Selection of adjuvants   
As previously stated, different immunopotentiators were tested in vivo in order to 
investigate their ability to target the superficial skin-resident antigen-presenting 
cells receptors. This strategy was based on the idea that the use of receptors agonists 
can better direct the antigen toward the APCs and enhance the immune response 
against the antigen.  
1. Toll-like receptors and their agonists  
Toll-like receptors (TLRs), named pattern recognition receptors (PRRs), are 
expressed in dendritic cells and macrophages, the sentinel cells of the innate 
immunity, and recognize highly conserved structural pathogen components (50).  
It is well known that the TLRs are able to stimulate the innate immune system and 
guide the magnitude and quality of an adaptive response (51). For this reason 
different molecules were selected in order to mimic the natural TLRs ligands and 
act as vaccine adjuvants (52). In the current study, Monophosphoryl Lipid A 
(MPLA) (53), a TLR4 agonist (TLR4a), and a synthetic compound, as TLR7 
agonist (TLR7a), were evaluated for a Meningococcal C glycoconjugate vaccine. 
These agonists were also formulated, and in vivo evaluated, with an o/w emulsion 
adjuvant. MPLA is a derivative of the lipid A portion of Salmonella Minnesota 
Re595 lipopolysaccharide (LPS) which retains the immuno-stimulatory properties, 
while lacking in toxicity. The TLR7a compound belongs to the 
imidazoquinolinamines class (54), generically known as SMIPs (small molecule 
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immune-potentiators), since they are able to modulate the immune response through 
immunoglobulin production (55), interferon and cytokine synthesis (56). 
2. Heat-labile enterotoxin from Escherichia coli (LT) mutant 
as GM1 receptor agonist 
Bacterial adenosine diphosphate (ADP)-ribosylating exotoxins are a group of 
adjuvants able to elicit or enhance the response toward a vaccine given via the 
cutaneous route (22-25). In particular, the heat-labile enterotoxin from Escherichia 
coli (LT) mutant, LTK63, is composed of two subunits coded by an operon; subunit 
A (LTA) is a 28-kDa enzyme and subunit B (LTB) is a 60-kDa protein, composed 
of five identical polypeptides (11.6 kDa) (57). 
The B pentamer structure contains the cellular receptor binding function. The 
principal receptor for LTB is the ganglioside GM1, a glycosphingolipid found 
ubiquitously on the cell surface of mammalian cells. The receptor binding activity 
of LTB is required for the uptake and internalization of the AB5 complex by host 
cells. The A subunit is the toxic portion of LT and is internalized and subsequently 
stimulates the cellular adenylate cyclase-cyclic AMP system, leading to dramatic 
and unregulated elevation of intracellular cAMP. In intoxicated gut epithelial cells, 
cAMP elevation results in massive secretion of electrolytes and water into the gut 
lumen, clinically manifesting as diarrhea. Therefore, the A subunit, responsible for 
the toxicity of LT, was modified in the active site, (serine-to-lysine substitution at 
position 63) and lacks total ADP-ribosylating activity, generating the LTK63 
mutant. This molecule has been reported to retain the potent adjuvant properties of 
LT (58). In particular, immunomodulatory effects of LTK63 appear to vary with 
vaccination route. For example, subcutaneous administration of LTK63 with a 
meningococcal serogroup C polysaccharide conjugate induced a dominant Th1 
response whereas intranasal administration induced a mixed Th1/Th2 response (58). 
Regarding intranasal and intramuscular delivery, LTK63 has reportedly enhanced 
APC activation and maturation, increased the proportion and total number of B-
cells as well as CD4
+
 and CD8
+
 T-cells, and both stimulated and enhanced both 
Th1-type cytokine responses (including IFN-γ and TNF-α) as well as Th2 responses 
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(59). In the current study the LTK63 was evaluated for a Meningococcal C 
glycoconjugate vaccine. 
3. β-glucan hexasaccharide as Dectin-1 receptor agonist  
β-(1-3)-glucans, which are the most abundant components of the fungal surface, are 
known to activate the innate immune response by interaction with the C-type lectin-
like Dectin-1 receptor (60-61). β-(1-3)-glucans binding to Dectin-1 induces the 
phosphorylation of a tyrosine of the immunoreceptor tyrosine-based activation 
motif (ITAM) in the cytoplasmic tail that elicits the secretion of inflammatory 
cytokines, such as tumor-necrosis factor (TNF) and IL-12 (62). β-glucans activated-
DCs are able to stimulate antigen specific CD8+ T-cell responses, inducing 
enhancement of antigen presentation, priming and expansion of antigen specific 
CD8+ T-cells (63-65). The interaction of β-(1-3)-glucans, which are triplic helix 
forming polysaccharides, with Dectin-1 has been detailed by diverse studies (66-
69). Linear structures have been found to bind best to the receptor in comparison to 
branched ones (70).
 
The minimal length required for interaction is 6-7 repeating 
units, although the binding becomes tighter as the length increases (69-70). In the 
current study the β-glucans hexasaccharide was evaluated for a Meningococcal C 
glycoconjugate vaccine. 
4.  α-GalCer analog as CD-1d receptor agonists  
α-GalactosylCeramide (α-GalCer), a potent lipidic agonist, found in the marine 
sponge Agelas mauritianus (71), strongly activates the invariant natural killer T 
(iNKT) cells, binding the lysosomal CD1d molecules. Upon activation, iNKT-cells 
modulate the activity of CD1d-expressing cells, such as DC and B-cells, via the 
costimulatory molecule CD40 ligand, and induce IFN-γ-dependent activation of NK 
cells, ultimately enhancing adaptive immune responses (72-73).  By influencing the 
activation state of an APC, α-GalCer plays an important role in the control of 
bacterial, parasitic, viral infections, as well as natural immunosurveillance, 
contributing to the regulation of a variety of processes, such as self-tolerance, tumor 
surveillance, and antimicrobial responses. It has been also observed that α-GalCer 
triggers enhanced antibody production in mice lacking MHC II, suggesting that 
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iNKT-cells can substitute for conventional CD4
+
 T-cells and provide assistance for 
maximal activation of B-cells (74). A α-GalCer analog was evaluated, in the current 
study, as agonist in co-delivery with the Meningococcal C glycoconjugate vaccine. 
5. Oil-in-water emulsion (o/w) adjuvant  
The oil-in-water nanoemulsion (o/w) adjuvant used in the present work is based on 
squalene droplets dispersed in an aqueous phase containing two non-ionic 
surfactants, Tween 80 and Span 85 (75). A similar nanoemulsion adjuvants namely 
the MF59 was the second adjuvant to be licensed in Europe for seasonal and 
pandemic influenza adjuvanted vaccines, demonstrating superior immunogenicity 
in comparison to aluminum salts (76-78) and excellent safety and tolerability (79) 
even after intradermal administration (80). The adjuvant effect of such 
nanoemulsion adjuvants was shown to be closely dependent on its formulation since 
none of the individual components induced comparable adjuvanticity (81). In the 
current study the nanoemulsion was tested in combination with the Meningococcal 
C glycoconjugate vaccine and further adjuvanted with the MPL immunopotentiator 
mentioned before, in order to improve the vaccine immunogenicity and evaluate the 
quality of the immune response.  
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Abstract 
Intradermal vaccine delivery is a promising alternative to the conventional 
intramuscular route. The skin layer is immunologically supported by a densely 
connected network of antigen presenting cells (APCs), while the skeletal muscle is 
loaded with a relatively sparse population of APCs. Thanks to this immunological 
machinery intradermal delivery induced a higher immunogenicity and a prolonged 
persistence of immune response for several antigens when compared to the 
intramuscular route. Moreover reduced pain, the potential for self-administration, 
speedier vaccine delivery and the prospective for the elimination of the “cold chain” 
increase the interest in intradermal vaccination. The scope of this study is to 
evaluate for the first time intradermal delivery as the route for the administration of 
the MenC glycoconjugate vaccine. A vaccine formulation suitable for intradermal 
delivery was prepared and its immunogenicity with or without adjuvants was tested 
in comparison to the classical intramuscular route. As adjuvants several Toll like 
receptor agonists, an LT mutant, a α-GalactosylCeramide analog and an oil in water 
emulsion were investigated in order to target skin-resident antigen-presenting cells. 
The intradermal delivery of MenC glycoconjugate vaccine showed superiority in 
terms of immunogenicity and serum bactericidal titers compared to the 
intramuscular administration even in absence of adjuvant. Importantly, the use of 
adjuvants allowed to reduce the number of doses administered and to modulate the 
quality of the immune response towards a more beneficial Th1 response. This 
approach has the potential to be extended to other meningococcal serogroups 
representing a promising strategy for the development of dermally administered 
multivalent glycoconjugate vaccines. 
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Introduction 
The dermal skin layer, that lies beneath the stratum corneum, is characterized by a 
densely network of immune modulating antigen presenting cells (APCs). While in 
the epidermis and dermis APCs are most significantly represented by Langerhans 
cells and dermal dendritic cells, the skeletal muscle is only loaded with a relatively 
sparse population of APCs. Importantly for several antigens intradermal delivery 
demonstrated an induction of a higher immunity and a prolonged persistence of 
immune response compared to the intramuscular route (82-89). Recently, enhanced 
anti-PCV immunogenicity was demonstrated, for a licensed pneumococcal-
conjugate vaccine when delivered with a skin patch and compared to the 
intramuscular injection of the same vaccine (90). Intradermal delivery might also be 
explored in order to increase patient compliance and so the volume of people 
vaccinated, increasing the reduction of the disease (91). Moreover certain 
formulations of intradermal vaccine delivery, such as patches, may abolish the 
necessity of the “cold chain,” which should decrease the cost of vaccine delivery 
and increase and facilitate distribution in developing countries (92). To further 
increase the benefits induced by intradermal delivery, adjuvants could be included 
in respective vaccine formulations. Commonly used adjuvants for transcutaneous 
immunization are the bacterial ADP-ribosylating exotoxins, including the heat-
labile enterotoxin from Escherichia coli (LT), and its mutant LTK63 (22-25, 58). In 
addition several Toll like receptor agonists (52), the oil in water emulsion (76-79, 
80) and a α-GalactosylCeramide analog (72-73) were evaluated in order to target 
skin-resident antigen-presenting cells (93-94) and enhance the immune response. 
Moreover the adjuvants might allow for the reduction of the number of doses 
administered and the modulation of the quality of the immune response (95). For all 
these reasons the purpose of this study was to evaluate intradermal delivery as a 
route for the administration of a MenC glycoconjugate vaccine. The capsular 
polysaccharides of the five meningococcal serogroups, A, B, C, W135, and Y, 
represent the major antigen for the conjugate vaccines (96-98). All the licensed 
meningococcal vaccines are administered by intramuscular injection. For MenC and 
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multivalent Men A, C, W135, and Y a first dose is recommended in infancy 
followed by a boost in adolescence or a single dose at the age of 11 years. The 
reduction of pain at the injection site and the ease of administration with the 
possibility of self-administration might increase the acceptance and the numbers of 
vaccinated people, especially adolescents, which for the first time must receive the 
meningococcus vaccines and have been generally reluctant to vaccination.  
To achieve our goal the MenC glycoconjugate vaccine was used as a model with 
the intent of extending this approach to further glycoconjugate vaccines. A 
formulation suitable for intradermal delivery was prepared and its immunogenicity 
with or without adjuvants was tested and compared to the classical intramuscular 
route.  
 
Materials and methods 
Tangential Flow Filtration (TFF) 
The MenC-CRM197 conjugate (component of Menveo®, Menjugate® vaccines) was 
concentrated by tangential flow filtration (Tandem Model 1082 - Sartorius) with a 
30 kDa MW cut-off, 200 cm
2
 membrane (Hydrosart Sartocon Slice 200 - Sartorius). 
The collected concentrate materials were then characterized for protein and 
polysaccharide content. 
High Performance Liquid Chromatography-Size Exclusion Chromatography 
(HPLC-SEC) 
The chromatographic method was performed as previously described (99). Data 
was processed using Chromeleon
TM
 6.7 software. Protein and conjugate peaks were 
detected at 214 and 280 nm and by fluorescence (emission spectrum at 336 nm, 
with excitation wavelength at 280 nm). 
High performance anion exchange chromatography with pulsed amperometric 
detection (HPAEC-PAD)  
The total saccharide content of MenC-CRM197 conjugate was determined by 
HPAEC-PAD as previously described (99). All chromatographic data was 
integrated and processed using Chromeleon
TM
 6.8 software. 
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Determination of 𝑪𝑹𝑴𝟏𝟗𝟕 protein content by BCA assay 
The CRM197 protein content in the sample was determined by colorimetric 
estimation using bicinchoninic acid (BCA) (Pierce™ BCA Protein Assay Kit) 
reagent with a bovine serum albumin (BSA) standard. The light absorbance at 562 
nm was measured using the Gen5
TM
 software and a tunable micro plate reader 
(BioTek). 
Production and size characterization of self-emulsifying oil-in-water emulsion 
adjuvant  
The oil-in-water (o/w) emulsion adjuvant was manufactured as previously described 
(75). The droplet size was measured on Malver Zetasizer (Malvern Instruments, 
Malvern, UK) by dynamic light after filtration through membrane filters.  
Immunogenicity testing in mice  
Protocols were approved by the Italian Ministry of Health. All mice were housed 
under specific pathogen-free conditions at the Novartis Vaccines Animal Resource 
Center. Groups of eight 6-week-old female BALB/c mice were immunized twice, 
four weeks apart, intramuscularly (i.m.)/intradermally (i.d.). The MenC-CRM197 
conjugate (1 μg/mouse of MenC) adjuvanted with alum hydroxide (AlumOH – 
internal compound) (0.2 mg/mouse) and delivered intramuscularly was used as a 
positive control. For i.m. immunization, 100 µl of CRM197 alone (2 μg/mouse) and 
MenC-CRM197 (1 μg/mouse of MenC) alone or co-delivered with 5 μg/mouse of the 
TLR4 agonist (TLR4a) Monophosphoryl lipid A (MPL - Avanti Polar), 25 
μg/mouse of a TLR7 agonist (TLR7a) (internal compound), 5 μg/mouse of heat 
labile enterotoxin (LTK63) and 5 μg/mouse of α-GalactosylCeramide analog (α-
GalAnalog) were injected. The same antigen/adjuvant dose was delivered 
intradermally in a 20 µL formulation using a 0.3 mL BD Micro-Fine syringe 
(30Gx8mm) inserted at a 45 degree angle. The vaccinations were dispensed in the 
back after shaving. In addition MPL adjuvant was tested in combination with 50% 
v/v o/w emulsion for the intradermal delivery. The appearance of nodules, 
erosion/scab, erythema and redness at the site of administration was monitored. 
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Serum samples were collected on days 14 and 42 and stored at -20 °C before 
analysis. 
Determination of MenC-specific antibody titers by ELISA  
Determination of anti-MenC specific total IgG and subclasses IgG1 and IgG2a titers 
was performed by ELISA using individual serum samples. Maxisorp plates (Nunc) 
were coated overnight at +4°C with 0.5 μg/well of MenC polysaccharide in PBS pH 
8,2 and blocked for 1 h at 37°C with 200 μL of 1% BSA (Sigma), in PBS. Serum 
samples were initially diluted in PBS, 0.1% BSA and 0.05% Tween-20 (Sigma), 
and serially diluted into coated and blocked plates. Bound MenC-specific IgG, IgG1 
and IgG2a were detected with alkaline phosphatase-conjugated goat anti-mouse IgG 
subclasses respectively (SouthernBiotech). Antibody titers, normalized with respect 
to the reference serum assayed in parallel, were obtained using IrisLab software. 
GraphPad Prism v.6.04 (GraphPad Software, La Jolla, CA) was used to graph and 
analyze data for statistical significance. Intergroup comparison was analyzed using 
the Mann-Whitney test.  
Determination of functional antibodies titers against Neisseria meningitidis 
Functional antibodies induced by vaccine immunization were analyzed by 
measuring the complement-mediated lysis of Neisseria meningitidis with an in vitro 
bactericidal assay using commercial pooled baby rabbit serum as a complement 
source (rSBA) (41). 
𝑪𝑹𝑴𝟏𝟗𝟕-specific T-cell intracellular cytokine responses  
Spleens were taken two weeks after the second immunization. Single cell 
suspensions were obtained from spleen grinding through a 70 μm nylon mesh (BD 
Falcon). Red blood cells were lysed and cells cultured in complete medium as 
previously described (100) For T-cell cytokine responses, 2 x 10
6
 cells/well were 
stimulated, overnight (ON) at 37°C, in the presence of anti-CD28/anti-CD49 Abs (4 
μg/mL each) (Pharmingen/eBioscience) and CRM197 (10 μg/mL), or with anti-
CD28/anti-CD49 alone (4 μg/mL each, unstimulated), or with anti-CD28/anti-CD49 
(4 μg/mL each) plus anti-CD3 (0.1 μg/mL) (Pharmingen). After stimulation 
overnight, 5 μg/mL Brefeldin A (Sigma Aldrich) was added and for an additional 4 
  
 
38 Chapter 2 
h incubated at 37°C. Cells were washed with 1x PBS (Gibco), and stained with 
LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit for 635 nm excitation (Life 
Technologies). Cells were fixed, permeabilized with Cytofix/Cytoperm (BD 
Biosciences), and stained with the following mAbs: anti-TNFα (BD Pharmingen), 
anti-IFN-γ (BioLegend), anti-IL-2 (BioLegend), anti-IL-4 (eBioscience), anti-IL-13 
(eBioscience) and anti-IL-17 (eBioscience). Stained cells were acquired using an 
LSR II special order system (Becton-Dickinson) and analyzed using FlowJo 
software (Tree Star).  
 
Results 
MenC-𝑪𝑹𝑴𝟏𝟗𝟕 glycoconjugate retains its integrity after the concentration 
process  
To obtain an appropriate MenC-CRM197 concentration, for the delivery of the 
established antigen dose in 20 µL of formulation volume, required for the 
intradermal immunization, the glycoconjugate was concentrated using the TFF 
process. The obtained material was characterized in order to define the total 
saccharide content of MenC-CRM197 conjugate by HPAEC-PAD (Table 2). The 
yield of the process, approximately total, is an indication of the optimal 
applicability of the process to the MenC-CRM197 glycoconjugate. To prove the 
absence of material degradation after the concentration process, the glycoconjugate 
was analyzed through HPLC-SEC (Figure 2a) and SDS-Page (Figure 2b). The 
chromatographic profile was comparable with the untreated material. Around 20 
fold more concentrated material was obtained and no impact on glycoconjugate 
integrity was evidenced by the weight ratio between MenC and CRM197 before and 
after the concentration process.   
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a 
1. MenC-CRM
197
 
2. MenC-CRM
197 
concentrated 
1       2 CRM197 MW 
198 - 
  
110 - 
72   - 
44   - 
b 
Table 2| Total saccharide content of MenC-𝑪𝑹𝑴𝟏𝟗𝟕 concentrated glycoconjugate 
 
Figure 2| Concentrated material characterization. (a) HPLC-SEC chromatographic profiles and 
(b) SDS page gel electrophoresis of respectively Neisseria meningitides capsular polysaccharides 
serogroup C and A, conjugated to the 𝐶𝑅𝑀197 carrier protein, before and after the concentration 
processes. Void volume 10.97 min, bed volume 24.79 min. 
  
 
Sample Total 
saccharide 
mg/mL
a 
Protein 
mg/mL
b 
Saccharide/Protein  
w/w
c 
Free 
Saccharide 
%
d 
Process yield 
%
e 
MenC-CRM
197
 0.69 1.21 0.57 < 4.4 - 
MenC-CRM
197
 
concentrated 
10.81 19.35 0.56 < 4,5 97 
MenA-CRM
197
 2.09 3.54 0.59 4.6 - 
MenA-CRM
197
 
concentrated 
7.82 15.39 0.51 3.9 98 
a: Recovered conjugate saccharide as determined by HPAED-PAD. 
b: Recovered protein as determined by microBCA. 
c: Weight ratio between MenC/MenA and CRM197  in the glycoconjugate. 
d: Recovered free saccharide as determined by HPAED-PAD. 
e: Yield obtained on protein content before and after concentration process as determined by microBCA.  
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MenC-𝑪𝑹𝑴𝟏𝟗𝟕 glycoconjugate shows superiority after intradermal immunization 
when compared to the intramuscular route  
In order to evaluate intradermal delivery as an alternative route for the 
administration of meningococcal vaccine an in vivo study was designed (Figure 3). 
Non-adjuvanted MenC-CRM197 was administered either intramuscularly or 
intradermally; whereas the glycoconjugate adjuvanted with AlumOH was used as a 
positive control for intramuscular administration only, given that AlumOH should 
not be used for intradermal delivery (29). Interestingly only the vaccine delivered 
intradermally and the AlumOH adjuvanted vaccine given intramuscular were able 
to elicit an anti-MenC immune response after the first immunization. For the non-
adjuvanted vaccine given intramuscularly two vaccine administrations were 
required to induce detectable antibody titers; moreover these titers were not superior 
to titers induced after a single injection with the vaccine given intradermally or the 
AlumOH adjuvanted vaccine given intramuscular. As seen after the first 
immunization also total IgG titers in sera from mice immunized with two doses of 
MenC-CRM197 intradermally showed comparable antibody titers to AlumOH 
adjuvanted vaccines given by the intramuscular route (Figure 3a). These data 
clearly show the superiority of the intradermal route when compared to the 
intramuscular administration and confirm the ability of a quicker onset of immune 
responses by either using a different route of administration or the use of adjuvants.  
For the protein alone anti-CRM197 IgG titers elicited after intradermal delivery 
resulted significant higher than that of the respective intramuscular titer, although 
the interquartile range bar associated with the intradermal response is very high 
(Figure 3b). While when comparing anti-CRM197 antibody titers induced by the 
MenC-CRM197 glycoconjugate vaccine the immune response was higher after 
intradermal delivery. Thus it seems that the presence of the polysaccharide 
component in respective glycoconjugate has an adjuvant effect versus the protein 
when intradermally administered. Importantly the elicited CRM197 specific IgG 
titers resulted in lower values than the AlumOH adjuvanted formulation given 
intramuscular. No adverse reactions such as nodules, erosion/scab, erythema or 
redness at the site of administration after intradermal immunization, were detected. 
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Figure 3| Systemic humoral responses to i.m. and i.d. administration of MenC-𝑪𝑹𝑴𝟏𝟗𝟕 alone, 
adjuvanted with alum hydroxide (AlumOH) and 𝑪𝑹𝑴𝟏𝟗𝟕. (a) MenC-specific and (b) 𝐶𝑅𝑀197-
specific IgG titers were analyzed after each immunization. Intergroup comparisons were analyzed 
using the Mann-Whitney statistical assay. Medians of MenC/𝐶𝑅𝑀197-specific IgG titers for i.m. and 
i.d. immunizations are reported.   
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Table 3| pValues (a) associated to groups in figure 3a (b) associated to groups in figure 3b. 
 
Oil in water emulsion and TLR4a increase the immunogenicity meningococcal 
glycoconjugate vaccine   
To evaluate if immunogenicity induced after intradermal immunization can be 
increased by the use of adjuvants two different adjuvants, an oil in water emulsion 
and a TLR4a, were evaluated either alone or in combination (Figure 4a). After a 
single immunization all adjuvanted groups induced antibody titers comparable or 
superior to titers induced by two immunizations with the non-adjuvanted vaccine 
given intramuscular. After two immunizations both adjuvants resulted in significant 
enhancement of the immune response against MenC polysaccharide in comparison 
with the glycoconjugate alone delivered i.d. and the AlumOH adjuvanted group 
given i.m. In order to evaluate if the immune response against MenC can be further 
maximized after intradermal vaccination, the TLR4a adjuvant was co-delivered 
with the oil in water emulsion; and significantly improved immune response was 
detected in comparison to the o/w adjuvanted formulations however no improved 
immunogenicity compared to the TLR4a single adjuvanted formulation was 
observed. With respect to anti-carrier immune responses all adjuvanted groups 
induced higher titers than the MenC-CRM197 alone, however comparable to the 
AlumOH adjuvanted formulation intramuscular delivered. No differences for anti-
CRM197 IgG titers were observed for the double adjuvanted formulation in 
comparison to both single adjuvanted formulations (Figure 4b).  
 
  
Groups pValue
MenC- i.m. vs MenC- i.d. 0,03
Groups pValue
i.m. vs i.d. 0,0093
MenC- +AlumOH i.m. vs MenC- i.d. 0,0019
i.d. vs MenC- i.d. 0,0017
a 
b 
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Figure 4| Systemic humoral responses to i.m. and i.d. administration of MenC-𝑪𝑹𝑴𝟏𝟗𝟕 alone, 
adjuvanted with oil in water emulsion (o/w) and TLR4 agonist (TLR4a) and 𝑪𝑹𝑴𝟏𝟗𝟕. (a) MenC-
specific and (b) 𝐶𝑅𝑀197-specific IgG titers were analyzed after each immunization. Intergroup 
comparison was analyzed using the Mann-Whitney statistical assay. Medians of MenC-specific and 
𝐶𝑅𝑀197-specific IgG titers for i.m. and i.d. immunizations are reported.  
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Table 4| pValues (a) associated to groups in figure 4a (b) associated to groups in figure 4b.  
 
Bactericidal titers correlate with the obtained ELISA titers  
The functionality of the elicited antibody titers post 2 was assessed by rabbit 
complement serum bactericidal assay (rSBA) (Table 4), a model that is considered a 
surrogate of protection for meningococcal antigens (101-102). In agreement with 
the total IgG titers the MenC-CRM197 associated rSBA titer after intradermal 
delivery was comparable to the AlumOH adjuvanted after intramuscular injection 
(Table 3); and a significant increase of rSBA titer was measured when TLR4a 
and/or emulsion adjuvanted formulations were delivered intradermally and 
compared to the respective titers elicited by non-adjuvanted CRM197 and MenC-
CRM197 formulations. As expected no bactericidal activity was elicited by the 
CRM197 for both immunization routes.  
Groups pValue
MenC- i.d. vs MenC- +o/w i.d. 0,0104
MenC- i.d. vs MenC- +TLR4a i.d. 0,0006
MenC- +AlumOH i.m. vs MenC- i.d. 0,0019
Groups pValue
MenC- i.d. vs MenC- +o/w i.d. 0,0002
MenC- i.d. vs MenC- +TLR4a i.d. 0,0002
MenC- +o/w i.d. vs MenC- +o/w+TLR4a i.d. 0,0002
MenC- +o/w i.d. vs MenC- +AlumOH i.m. 0,0021
MenC- +TLR4a i.d. vs MenC- +AlumOH i.m. 0,0003
b 
a 
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Table 5| Bactericidal titers for mice sera post 2 analyzed by measuring the complement-mediated 
lysis of Neisseria meningitidis. 
 
Immunopotentiators for intradermal delivery MenC-𝑪𝑹𝑴𝟏𝟗𝟕 glycoconjugate 
vaccine  
In addition to the tested TLR4a and the o/w emulsion adjuvant, MenC-CRM197 
glycoconjugate vaccine was adjuvanted with three alternative adjuvants: TLR7a, 
LTK63 and αGalAnalog, in order to evaluate novel adjuvants able to target skin-
resident antigen-presenting cells. Intramuscular and intradermal routes were 
investigated (Figure 5). Data obtained confirmed that in absence of adjuvant 
immunogenicity of MenC glycoconjugate vaccine when delivered intradermally not 
only showed a quicker on-set but was also significant higher in comparison to 
respective intramuscular administration. For both immunization routes, -intradermal 
and intramuscular - and after both - the first and the second - immunizations, total 
IgG titers induced in presence of immunopotentiators were higher than the titer of 
the non-adjuvanted formulation. Interestingly for the intramuscular route the 
presence of adjuvants seem to be mandatory in order to elicit an immune response 
after a single immunization only; whereas non-adjuvanted vaccine given 
intradermally is able to induce already detectable immune response after the first 
immunization. Moreover the MenC-specific IgG titers, obtained in sera post1, 
associated to all adjuvants tested and delivered intradermally are comparable to the 
titer of the antigen alone delivered intramuscularly after two immunizations.  
Vaccine
rSBA titer
MenC - C11strain
i.m. i.d.
+
- <16 <16
MenC-
- 128 8192
AlumOH 8192 -
o/w
/
32768
TLR4a 131072
o/w+TLR4a 65536
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Figure 5| Systemic humoral responses to i.m. and i.d. administration of MenC-𝑪𝑹𝑴𝟏𝟗𝟕 alone and 
adjuvanted with TLR4/TLR7 agonists (TLR7a – TLR4a), LTK63 and αGalAnalog. MenC-specific 
IgG titers were analyzed after the first and the second immunization. Intergroup comparison was 
analyzed using the Mann-Whitney statistical assay. Medians of MenC-specific IgG titers for i.m. and 
i.d. immunizations are reported.  
Table 6| pValues  associated to groups in figure 5 
 
 Bactericidal titers correlate with the obtained ELISA titers  
In agreement with the total IgG titers a significant increase of bactericidal activity 
was measured when MenC-CRM197 glycoconjugate was intradermally administered 
and compared to the intramuscular route. For both immunization routes all the 
adjuvants tested increased serum bactericidal titers and TLR4a and LTK63 
adjuvanted formulations seem to induce higher titers when delivered intradermally 
in comparison to the two respective formulations given through the intramuscular 
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route. Whereas no differences were observed between the two immunization routes 
in presence of the TLR7a and αGalAnalog adjuvanted formulations. 
 
Table 7| Bactericidal titers for mice sera post 2 analyzed by measuring the complement-mediated 
lysis of Neisseria meningitidis. 
 
Immunopotentiators induces a Th1 shift  
To determine the quality of the immune response, post 2 mice sera were analyzed 
for anti-MenC-specific IgG1 and IgG2a titers (Figure 6). The presence of TLR4a 
and TLR7a elicited higher IgG2a antibody titers than the LTK63 adjuvanted 
vaccine formulations and the Th1 isotype shift was induced for both i.m. and i.d. 
immunization routes. On the contrary, the αGalAnalog adjuvant enhances the Th2 
isotype antibody response. Remarkably LTK63 induced a Th1 shift in a more 
predominant way after intradermal delivery, confirming previously reported data 
obtained after the mucosal administration of Influenza vaccine (100), where it 
seems that the ability of the LTK63 adjuvant to shift immune responses to a more 
dominant Th1 profile is immunization route dependent. This result was also 
confirmed by the CRM197-specific T-cell responses in spleens evaluated by 
intracellular staining and flow cytometry. The percentage of CD4
+
 CD44
high
 T-cells 
producing IL-2, IL-4/IL-13, IL-17, IFN-ɣ and TNFα were analyzed (Figure 7). 
CRM197 -specific T-cell responses in spleens, after LTK63 administration, showed 
that IFN-ɣ production was elicited only after intradermal delivery and higher TNFα 
and IL-2 cytokines production occurred after intradermal delivery in comparison to 
Vaccine
rSBA titer
MenC - C11strain
i.m. i.d.
MenC- +
- 256 4096
TLR4a 65536 131072
TLR7a 16384 16384
LTK63 32768 65536
αGalAnalog 16384 16384
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the intramuscular route. No particular differences were observed for the other 
presented cytokines between i.m. and i.d. delivery (data not shown). 
Figure 6| Systemic humoral responses to i.m. and i.d. administration of MenC-𝐶𝑅𝑀197 (Ag) alone 
and adjuvanted with TLR7/TLR4 agonist (TLR7a/TLR4a), LTK63 and αGalAnalog are reported. 
MenC-specific IgG1/IgG2a titers ratio of mice sera post 2 are reported. 
Figure 7| Intramuscular and intradermal immunizations elicited 𝐶𝑅𝑀197 -specific T-cell responses. 
Mice were vaccinated i.m. or i.d. with MenC-𝐶𝑅𝑀197 (Ag) alone or in combination with LTK63. 
CD4
+
 T-cell cytokine responses to 𝐶𝑅𝑀197 were evaluated in spleen two weeks after the second 
immunization. T-cell responses were calculated by subtracting fluorescence percentages of 
untreated samples from the 𝐶𝑅𝑀197-stimulated samples. Untreated mice (naïve) were used as 
negative controls  
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Discussion 
In the present study it has been shown that by using Tangential Flow Filtration 
(TFF), a scalable and robust process, it is possible to prepare highly concentrated 
MenC glycoconjugate vaccines for subsequent intradermal delivery. Importantly, it 
was demonstrated that the process does not affect the integrity and the 
immunogenicity of the antigen. The characterization data generated, along with the 
systemic immune response in mice, clearly establish TFF as a suitable process for 
the concentration of MenC glycoconjugate vaccine. Moreover this scalable 
technique might help to process large batches of MenC glycoconjugate vaccine and 
could be easily adapted to further glycoconjugate vaccines as have already been 
tested for MenA-CRM197 glycoconjugate (data not shown). The concentrated 
material was used to evaluate the administration of the MenC glycoconjugate 
vaccine through the intradermal route in comparison to intramuscular delivery. 
Superiority, in term of immunogenicity and protection, of the intradermal delivery 
was demonstrated. Considering that the non-adjuvanted vaccine given intradermally 
is able to induce a detectable immune response after the first immunization and that 
comparable antibody titers to AlumOH adjuvanted formulations injected 
intramuscularly, after one and two doses, are achieved the intradermal route has the 
potential to allow the elimination of AlumOH from the vaccine formulation.  
The good intradermal immunogenicity of the MenC glycoconjugate vaccine might 
be explained by the presence of several receptors on the surface of Langerhans 
cells, the primary antigen presenting cell in the skin, which allow a better cell 
targeting and activation and consequently, a more efficient antigen presentation 
than other dendritic cell subpopulations. Whereas conventional intramuscular route 
of vaccine administration may limit the magnitude and the quality of the immune 
response by targeting and activating less immunologically active sites.  
It was demonstrated that the use of immunopotentiators can further enhance the 
immunogenicity and increase bactericidal activity after intradermal delivery; 
depending on the adjuvant used an evident shift in the quality of the immune 
response is observed. For meningococcus, there are indications that the induction of 
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the IgG2a subclass is highly protective (103). Interestingly the TLR4 agonist and 
TLR7 agonist induced increased IgG2a antibody  titers – thus a Th1 shift - 
independently from the route of immunization, while LTK63 induced the shift 
toward a Th1 response in a more predominant way after intradermal delivery, 
therefore confirm results obtained after mucosal delivery and published elsewhere 
(100). Moreover LTK63 induced INFɣ production from CD4+ T-cells after 
intradermal but not after intramuscular delivery confirming respective evidence. 
Regarding the αGalCer analog, the enhanced IgG1 antibody production indicates 
this adjuvant as more convenient to be used to treat diseases that need a 
predominant Th2 response. It also has been demonstrated that the oil in water 
emulsion adjuvant can be used for the intradermal administration of a 
glycoconjugate vaccine, increasing its immunogenicity. In the present studies the 
pre-clinical observation revealed that the tested adjuvants were well-tolerated, and 
that any evident local reaction was evidenced. A more in depth analysis is required 
to better investigate the safety profile of these compounds after intradermal 
delivery.  
In the context of anti-carrier immunity, the administration of the CRM197 protein 
alone did not show a good immune response against the protein for both routes of 
immunization; at the same time the elicited CRM197 –specific IgG titers after 
MenC-CRM197 intradermal administration resulted in higher levels than the same 
formulation administered intramuscularly. In previous studies (18, 104-105) it was 
demonstrated how polysaccharides that are weak receptor binders can be turned into 
more potent agonists by their multivalent presentation through conjugation to a 
protein core. In that case the MenC, as saccharide, might have acquired an immune 
stimulant role for skin dendritic cell after its conjugation to the CRM197 carrier 
protein. Nevertheless anti-CRM induced antibody titers after intradermal vaccine 
delivery remained significant lower when compared to anti-CRM titers induced 
with the Alum adjuvanted formulation given intramuscular. Results published by 
Pecetta et al indicate that anti-CRM immunity might even improve the anti-
saccharide response for corresponding glycoconjugates vaccines (106). Therefore 
enhanced CRM197 –specific IgG titers after intradermal delivery of MenC-CRM197 
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should not negatively impact the anti-saccharide response of a subsequent 
CRM197 glycoconjugate vaccination. 
All the above findings demonstrate that the modulation of vaccine formulation 
through careful selection of antigen, adjuvants and the route of administration, is an 
important approach for the development of effective vaccines. Thus promising 
adjuvants combined into new vaccine formulations and devises as for example 
microneedle technologies might lead to the development of multivalent 
meningococcal glycoconjugate vaccines given by the dermal route. Importantly, 
recent studies among volunteers have demonstrated a clear preference for 
intradermal route of vaccine delivery over the conventional i.m. route (107). 
Several factors might contribute to this preference, such as needle phobia, lack of 
pain, and the potential for self-administration.  
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Supplementary data  
 β-glucan hexasaccharide as adjuvant: co-delivered and  
conjugated to MenC-𝑪𝑹𝑴𝟏𝟗𝟕 glycoconjugate  
 
Introduction 
To better evaluate the β-(1-3) hexasaccharide as adjuvant for MenC-CRM197, in 
addition to the previous tested adjuvants, it was delivered in physical mix as well as 
conjugated to CRM197 carrier protein and in vivo evaluated after intramuscular, 
intradermal and subcutaneous vaccinations. As already reported, β-(1-3)-glucans 
and are able to activate innate immunity by the interaction with the Dectin-1 
receptor (66-69). In chapter 4 the conjugation of β-glucan hexasaccharide to the 
CRM197 model antigen is proposed as strategy to test the capability to enhance the 
immune response toward a protein model antigen in comparison to the here 
presented glycoconjugate model antigen. 
 
Materials and methods 
Immunogenicity testing in mice  
Protocols were approved by the Italian Ministry of Health. All mice were housed 
under specific pathogen-free conditions at the Novartis Vaccines Animal Resource 
Center. For intramuscular (i.m.) and intradermal (i.d.) vaccinations, groups of eight 
6-week-old female BALB/c mice were immunized twice, four weeks apart. 100 µl 
of MenC-CRM197 (1 μg/mouse of MenC) alone or co-delivered with 25 μg/mouse 
of β-glucan hexasaccharide were injected intramuscularly. The same 
antigen/adjuvant dose was delivered intradermally in a 20 µL formulation using a 
0.3 mL BD Micro-Fine syringe (30Gx8mm) inserted at 45 degree angle. The 
vaccinations were dispensed in the back after shaving. The appearance of nodules, 
erosion/scab, erythema, redness at the site of administration was monitored. Serum 
samples were collected on days 14 and 42 and stored at -20 °C before analysis. For 
subcutaneous (s.c.). vaccination, groups of eight 6-week-old female BALB/c mice 
were immunized three times, three weeks apart. 200 µl of MenC-CRM197 (1 
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μg/mouse of MenC) and MenC-CRM197-hexa (1 μg/mouse of MenC, 0,25 
μg/mouse of hexasaccharide) were injected. Serum samples were collected on days 
20, 35 and 56 and stored at -20 °C before analysis 
Determination of MenC-specific antibody titers by ELISA  
See manuscript above. 
 
Results and conclusions 
 β-glucan hexasaccharide co-delivered with MenC- 𝑪𝑹𝑴𝟏𝟗𝟕  
glycoconjugate doesn’t increase the immune response to MenC 
polysaccharide 
After two immunizations, β-glucan hexasaccharide co-delivered with the antigen 
didn’t show an adjuvant effect as revealed by the absence of a statistical 
significance between the adjuvanted and non-adjuvanted formulations for both 
immunization routes (Figure 8). In the presented study we showed the lack of β-(1-
3)-glucan hexasaccharide adjuvant effect when co-delivered with the antigen.  
Figure 8| Systemic humoral responses to i.m. and i.d. administration of MenC-𝑪𝑹𝑴𝟏𝟗𝟕 alone and 
adjuvanted with β-glucan hexasaccharide (Hexa). MenC-specific IgG titers were analyzed after the 
second immunization. Intergroup comparison was analyzed using the Mann-Whitney statistical 
assay. Medians of MenC-specific IgG titers for i.m. and i.d. immunizations are reported.  
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 Conjugation of hexasaccharide to 𝑪𝑹𝑴𝟏𝟗𝟕 carrier doesn’t increase the 
immune response to MenC polysaccharide 
After three immunizations, total IgG titer induced by MenC-CRM197-hexa 
conjugate is comparable to the MenC-CRM197 control after subcutaneous 
immunization. Β-glucan hexasaccharide conjugated with the antigen didn’t show an 
adjuvant effect as revealed by the absence of a statistical significance between the 
two tested formulations (Figure 9). This result can be explained by the steric 
conformation of the conjugate. The long MenC polysaccharide chain eventually 
interfered with the accessibility of the short hexasaccharide chain to the Dectin-1 
receptor and consequently no adjuvant effect was observed. 
Figure 9| (a) Systemic humoral responses to s.c. administration of MenC-𝑪𝑹𝑴𝟏𝟗𝟕 alone and 
conjugated with β-glucan hexasaccharide (MenC-𝑪𝑹𝑴𝟏𝟗𝟕-hexa). MenC-specific IgG titers 
were analyzed after the second and third immunization. Intergroup comparison was analyzed using 
the Mann-Whitney statistical assay. Medians of MenC-specific IgG titers for s.c. immunizations are 
reported. (b) Graphic representation of MenC-𝑪𝑹𝑴𝟏𝟗𝟕-hexa compound.
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The impact of TLR7 agonist conjugation to anti 
serogroup C meningococcal glycoconjugate 
vaccine  
  
 
56 Chapter 3 
 
MenC
CRM197
TLR7a
MenC
TLR7aCRM197
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a 
Two different approaches of agonist conjugation  
As previously stated in chapter 2, agonists of Toll like receptor 7 (TLR7a) can 
activate innate immunity and initiate a cascade of immune responses that can 
impact the magnitude and the persistence of the immune response. These features 
render TLR7a a very attractive class of small molecules for the development of 
adjuvants for vaccination (108-109). Recently, Vecchi et al has proven that 
conjugation of TLR7a to an anti-Streptococcus pneumoniae protein antigen 
increases the immunogenicity and reduced the vaccine dose required to elicit 
protective immunity (125). In this chapter the conjugation of TLR7a to the antigen 
is proposed as a viable strategy to ensure codelivery of TLR7a/antigen and to 
transport the ligand to the receptor, to promote its intracellular accumulation and to 
favor the receptor activation. Two different approaches of TLR7 agonist 
conjugation to MenC-CRM197 glycoconjugate vaccine were investigated in vivo:  
1. TLR7a conjugation to CRM197 carrier protein (Figure 1a); 
2. TLR7a conjugation to MenC polysaccharide (Figure 1b); 
The obtained findings for the TLR7a conjugation to CRM197 carrier protein 
approach were reported in a manuscript submitted to the European Journal of 
Pharmaceutics and Biopharmaceutics, instead the results obtained for the TLR7a 
conjugation to MenC polysaccharide approach were organized as supplementary 
data.    
Figure 1| Graphic representation of the two different approaches of TLR7 agonist 
conjugation to MenC-𝑪𝑹𝑴𝟏𝟗𝟕 glycoconjugate vaccine.  
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Abstract 
Agonists of Toll like receptor 7 (TLR7a) have emerged as important targets to 
develop novel adjuvants for vaccination. Conjugation of a small immunopotentiator 
molecule has been proposed to vehicle the ligand to the receptor, localize its action 
and reduce toxicity. However, the effect of conjugation on the immunogenicity of 
carbohydrate-based vaccines is unknown. In this study we synthesized a 
tricomponent anti-Neisseria meningitidis serogroup C (MenC) glycoconjugate 
vaccine composed of MenC oligosaccharide antigens covalently linked to the 
carrier protein CRM197, to which a TLR7a has been in turn conjugated. The 
tricomponent vaccine demonstrated in vitro to activate the TLR7 comparably to the 
unconjugated ligand. The impact of the adjuvant conjugation in the anti-
carbohydrate immune response was evaluated in mice by comparing the 
tricomponent vaccine to a MenC-CRM197 conjugate, prepared through the same 
conjugation chemistry and co-administered with the unconjugated TLR7a. A 
commercialized anti-MenC glycoconjugate was used as further control to determine 
the influence of the coupling approach and level of carbohydrate incorporation on 
the anti-MenC immune response. The possible additive effect of co-administration 
with Alum hydroxide (AlumOH) was also examined. Results clearly showed that 
conjugation of the TLR7a enhances the anti-carbohydrate response. This effect was 
less pronounced than the co-administration of a commercial glycoconjugate with a 
standard dose of TLR7a-phosphonate adsorbed on AlumOH. The reduction of sugar 
incorporation which is needed for the conjugation of the TLR7a lessens the anti-
carbohydrate response, and is therefore a parameter which counteracts the 
enhancement of the immune response produced by the adjuvant conjugation. While 
absorption on AlumOH offers more flexibility in the administered dose of TLR7a, 
conjugation of the small immunopotentiator molecule could be particularly suited 
for vaccination via skin delivery, where insoluble salts of aluminum cannot be used 
because of their reactogenicity. These findings pave the ground for the rational 
design of improved adjuvanted glycoconjugate vaccines and for establishing novel 
and safer vaccination routes. 
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Introduction 
Agonists of Toll like receptor 7 (TLR7a) can activate innate immunity and initiate a 
cascade of immune responses that can impact the magnitude and the persistence of 
the immune response. These features render TLR7a a very attractive class of small 
molecules for the development of adjuvants for vaccination (108-109). Different 
potent synthetic ligands for TLR7, based a variety of chemical scaffolds (8-
oxoguanosines, 8-oxo-3-deazapurines, 6-amino-9-benzyladenine, 
imidazoquinolinamines and benzonaphtyridine), have been reported (110-115). 
Initial studies have proven the adjuvant effect of the imidazoquilinone imiquimod 
formulated as cream for dermal application (Aldara®) (116), and administered 
locally in mice after subcutaneous immunization with ovalbumin (OVA). Likewise, 
topical treatment with Aldara®, following to subcutaneous immunization of mice 
with Plasmodium falciparum circumsporozoite peptides, enhanced the anti-peptide 
response (117). The rapid production of cytokines induced by TLR7a is responsible 
for a proinflammatory response which besides the desired adjuvant effect can lead 
to toxicity (118). For instance, both oral and topical preparations of imiquimod and 
resiquimod and other small-molecule TLR7/8 agonists can exhibit serious side 
effects, including emesis and liver disfunction (119). Reduction of toxicity can be 
achieved by lower doses of administered TLR7a. Conjugations to lipids (113) or to 
polysaccharides (120) have been proposed to improve immunostimulatory potency 
and pharmacodynamics, while reducing the administered dose. Localization of the 
small molecules in the administration site appears as an important prerequisite to 
modulate the inflammatory effect and reduce possible toxicity in the use of TLR7a. 
In addition, pH-dependent concentration of the TLR7a in the MHC class II loading 
compartment (MHCII) has been proven important for activation of dendritic cells 
(121). Therefore co-localization of antigen and TLR7a create a favorable synergy in 
the activation of the immune system. Different strategies have been pursued for co-
administration of peptide or protein antigens while achieving temporal and spatial 
restriction of TLR7a induced inflammation. Encapsulation of resiquimod (R-848) 
into liposomes showed to increase the anti-OVA antibody response more 
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effectively than the simple administration of OVA and R-848 (119). Wu et al 
showed that absorption onto AlumOH of TLR7a phosphonates can remarkably 
enhance the immune response (antibody titers and functional activity) of a 
recombinant protein antigen directed to Neisseria meningitidis serogroup B and of 
the anti-B. Anthracis recombinant protective antigen (115). Conjugation of TLR7a 
to the antigen has been proposed as a viable strategy to ensure codelivery of TLR7a 
and antigen.  The protein mouse serum albumin (MSA) was tested as delivery 
system for intranasal or intratracheal administration to increase the potency of the 
small molecule, while reducing the systemic cytokine syndrome (114). Covalent 
linkage of the TLR7/8a to the HIV-1 gag protein was demonstrated crucial to 
generate CD4+ and CD8+ T-cell responses in both mouse and non-human primates 
(122-123). This would result from robust accumulation of DCs in regional lymph 
nodes, compared to administration of unconjugated TLR7 ligand (124). 
Recently, Vecchi et al has proven that conjugation of TLR7a to an anti-
Streptococcus pneumoniae protein antigen increases the immunogenicity and 
reduced the vaccine dose required to elicit protective immunity (125). In the present 
study we exploited the conjugation of TLR7 to an anti-meningococcal serogroup C 
glycoconjugate vaccine as a strategy to enhance the anti-carbohydrate immune 
response. Different glycoconjugates are currently used in the prevention of different 
microbial infections, including meningitis and pneumonia (126). The capability of 
carbohydrates, which are per se T-cell independent antigens, to engage a T-cell 
memory response is strictly dependent to the covalent bond with a protein carrier 
(127). This linkage ensures uptake of the glycoconjugate by antigen processing 
cells and re-exposition of the generated peptides or glycopeptides in complex with 
the MHCII. We anticipated that the covalent linkage of the TLR7a to the 
glycoconjugate could vehicle the ligand to the receptor, promote its intracellular 
accumulation and favor the receptor activation. To test this hypothesis we 
conjugated the TLR7a to the protein component of a glycoconjugate composed of 
the MenC oligosaccharide andCRM197. This serogroup causes one third of 
meningococcal cases reported with US, with a significant high case fatality ratio 
(14.6%) (128). Outbreaks of meningococcal disease related to serogroup C have 
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been identified also in Brazil and Australia (129-130). Monovalent and multivalent 
vaccines are currently available for the prevention of this infection (131), therefore 
an anti-MenC conjugate appeared an attractive target for comparison of the immune 
response towards the novel constructs with an existing vaccine. After developing a 
synthetic approach for the preparation of the tricomponent MenC-CRM197-TRL7a 
conjugate (1), composed of the MenC (B-cell epitope), CRM197 as (T-cell epitope) 
and the small immunopotentiator molecule, the construct was first evaluated in vitro 
to ascertain the effective ligand-receptor binding. Then the impact of the adjuvant 
conjugation in the anti-carbohydrate immune response was evaluated in vivo by 
comparison to the MenC-CRM197 conjugate (2), prepared through the same 
conjugation chemistry and co-administered with the unconjugated TLR7a. A 
commercialized anti-MenC glycoconjugate (3) (component of Menveo®, 
Menjugate® vaccines) was used as further control to determine the influence of the 
coupling approach and level of carbohydrate incorporation on the anti-MenC 
immune response. The possible additive effect of co-administration with AlumOH 
was also examined. In the animal studies, co-administration of MenC 
glycoconjugate (3) and a small molecule-phosphonate adsorbed on AlumOH, 
previously reported to confer a strong adjuvant  effect towards protein antigens, was 
used a benchmark. Evaluation of antibody levels and bactericidal activity of the 
elicited sera enabled to ascertain the adjuvant effect of the TLR7a covalently linked 
to MenC-CRM197 conjugate. 
 
Materials and methods 
Preparation of CRMemcs (4) 
The protein was modified as previously described (132). Briefly, 1.52 mg of EMCS 
linker (Pierce, Thermo) were dissolved in 50 µl of DMSO, and 44 µl of the 
prepared mixture (10 equiv.) were added to a solution of CRM197 (obtained from 
Novartis Vaccines Manufacturing) (1 ml of 32.5 mg/ml stock solution) in 400 µl of 
100 mM NaPi, 1 mM EDTA pH 8.1. The solution was stirred for 3 h. CRMemcs     
was purified by 30 kDa Vivaspin filter, dialyzing against 10 mM NaPi, 1 mM EDTA 
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pH 7.2 (x 5  dialysis cycles), and its content was quantified by colorimetric assay 
(MicroBCA assay, Pierce, Thermo). The linker/protein molar ratio was determined 
by MALDI-TOF mass spectrometry analysis run in an UltraFlex III MALDI-
TOF/TOF instrument, (Bruker Daltonics) in linear mode and with positive ion 
detection. The samples for analysis were prepared by mixing 2.5 μl of product and 
2.5 μl of sinapinic acid matrix (Sigma); 2.5 μl of each mixture was deposited on a 
samples plate, dried at room temperature for 10 min, and subjected to the 
spectrometer. An average of 6.5 linkers was introduced.  
 
Conjugation of TLR7a to CRMemcs (4) 
TLR7a (5 mg, 0.085 µmol, 500 μ of a 8.75 mg/ml stock solution) was diluted with 
500 μl of 350 mM NaPi, then TLR7a was added (20 equiv. dissolved in 20 μl of 
DMSO). After dialyzing against 150 mM NaCl, 10 mM NaPi pH 7, the protein was 
recovered in 10 mM NaPi and the protein content was estimated by microBCA 
(Pierce, Thermo). Conjugate  5  was recovered in 90% yield. 
 
Preparation of MenC-SH (8) 
MenCcysteamine oligomer  7  was first obtained by reaction of MenCsidea  6  
oligosaccharide with average degree of polymerization (avDP) of 20 and 2-
Mercaptoethylamine-2'-thiopyridine disulfide (prepared as reported in literature 
(133)) (5 equiv) at 20 mg/ml concentration in 1:9 H2O:DMSO (5 ml) containing 
10% v/v of triethylamine. After stirring for 3 h at room temperature, the 
oligosaccharide was precipitated by addition of 9 volumes of ethyl acetate. The 
solid was purified on a G15 Sephadex column (GE Healthcare), eluting with 20 
mM NaCl. Fractions containing the oligomer  7  were combined and concentrated 
to obtain a concentration (sialic acid based) of 20 mg/ml in 10 mM sodium 
phosphate (NaPi) pH 7.2. To release the free thiol groups, compound  7  was treated 
with 3 equiv. of 0.5 M TCEP and stirred for 3 h. After purification on a G15 
Sephadex column (GE Healthcare), the thiol groups of MenC-SH  8  were 
estimated before conjugation. 
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Conjugation of MenC-SH (8) to CRMemcs-TRL7a (5) and CRMemcs (4) 
Glycoconjugate  1  was prepared by incubating MenC-SH  8  with CRMemcs-
TLR7a  5  (30:1 mol saccharide/protein) in 10 mM NaPi pH 7.2, 1 mM EDTA.  
The control MenC-CRMemcs 2 was prepared as previously reported (133). For 
purification, the crude mixtures were precipitated from aqueous ammonium sulfate, 
reconstituted in 3 M NaCl and purified on a High Trap Phenyl sepharose column 
(GE Healthcare) with a gradient 3 M NaCl to remove the unconjugated oligomers. 
Fractions containing the glycoconjugate were pooled and concentrated on a 30 kDa 
Vivaspin filter (Sartorius) to be reconstituted with 10 mM NaPi pH 7.2. The protein 
content of final glycoconjugates was determined by colorimetric assay micro-BCA, 
while the saccharide content and free saccharide % by HPAEC-PAD analysis (100). 
Endotoxin levels were measured for all the prepared glycoconjugates and resulted 
below 4 EU/µg. 
 
NF-κB Luciferase Reporter Assay  
TLR-specific activation assays were performed using human embryonic kidney 293 
(HEK293) cells expressing luciferase under control of the NF-κB promoter and 
stably transfected with human TLR7. HEK293-transfected cells were maintained in 
DMEM complemented with 4.5 g/l glucose and HEPES (Invitrogen), 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin solution (Invitrogen), puromycin 
(5 μg/ml), and blasticidin (5 μg/ml). 
For the NF-κB luciferase assay, 25000 cells/well were seeded in 90 μl of complete 
DMEM without antibiotics in 96-well μClear® luciferase plates (PBI International) 
and incubated for 24 h at 37 °C. 10 μl of serial 5-fold dilutions of TLR7a in 
PBS+10% DMSO (0.0001–10 µM in 1% DMSO final concentration in the assay) 
were added. All compound concentrations were tested in duplicate. After incubation 
for 6 h at 37 °C, supernatants were discarded from each well, and cells were lysed 
for 20 min at room temperature using 20 μl/well of 1:5 diluted ’passive lysis buffer‘ 
(Promega). Luciferase assay reagent (100 μl/well) (Promega) was added, and 
emitted light was immediately quantified using a luminometer Lmax II384 
(Molecular Devices). NF-κB activation of cells stimulated with TLR7a is expressed 
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as fold-increase of emitted light over the average result of PBS+1% DMSO-
stimulated control cells. 
 
Immunization studies 
Protocols were approved by the Italian Ministry of Health. All mice were housed 
under specific pathogen-free conditions at the GSK Vaccines Animal Resource 
Center. For both in vivo studies, groups of ten 6-week-old female BALB/c mice 
were immunized by intramuscular injection (i.m.) of 0.5 μg/mouse carbohydrate-
based dose of glycoconjugates on days 1 and 14. TLR7a was used as 
immunopotentiator at a dose of 0.5 μg/mouse, either conjugated or co-delivered 
with compound    . Coadministration of glycoconjugate  3  and SMIP7,10 (5 μg) 
adsorbed on AlumOH was the positive control. For i.m. immunization with 
AlumOH, a dose of 200 μg/mouse physically mixed with the conjugates was used 
(134). PBS and AlumOH were the negative controls. Serum samples were collected 
on days 0, 14 and 28 and analyzed by ELISA for their anti-MenC IgG levels. 
 
Determination of anti-MenC antibody titers by ELISA 
Determination of anti-MenC specific total IgG and subclasses IgG1 and IgG2a titers 
was performed by ELISA using individual serum samples. Maxisorp plates (Nunc) 
were coated overnight at +4°C with 5 μg/well of MenC polysaccharide solution in 
pH 8.2 PBS buffer, and blocked for 1 h at 37°C with 200 μl of 1% BSA (Sigma), in 
PBS. For the IgG ELISA assay, serum samples were initially diluted in PBS (1:25 
for pre immune, 1:200 for a reference serum, 1:50–1:100 for test sera), 0.1% BSA 
and 0.05% Tween-20 (Sigma), transferred into coated and blocked plates and 
serially diluted. Bound MenC-specific IgG, IgG1 and IgG2a were detected with 
alkaline phosphatase-conjugated goat anti-mouse IgG, IgG1 and IgG2a respectively 
(SouthernBiotech). Antibody titers, normalized respect to the reference serum 
assayed in parallel, were obtained using IrisLab software. GraphPad Prism v.6.04 
(GraphPad Software, La Jolla, CA) was used to graph and analyze data for 
statistical significance. Intergroup comparison was analyzed using the Mann-
Whitney test.  
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Rabbit serum bactericidal assay (rSBA) 
Functional antibodies of pooled sera induced by vaccine immunization were 
analyzed by measuring the complement-mediated lysis of N. meningitidis with an in 
vitro bactericidal assay described in the literature (135). SBA titers were 
conventionally assigned when two successive sera dilutions lead to at least to 90% 
bacteria killing and were expressed as the reciprocal serum dilution which results in 
50% of bacteria killing. MenC11 was used as reference strain. 
 
Results and Discussion 
Glycoconjugate assembly 
MenC CPSs consists of  (29)-linked polysialic acids partially acetylated at 7- or 
8-OH, respectively (Figure 2) (136). A well-established strategy to produce an anti-
MenC glycoconjugate vaccine consists of the hydrolysis of the native 
polysaccharide, followed by sizing of medium length oligomers (136) and reductive 
amination to provide the terminal amine group for final conjugation with the lysine 
residues of the protein via active ester chemistry (100).  
Figure 2| Glycoconjugates prepared for evaluating the effect of covalently linked TLR7a to 
CRM197; emcs = N-(ε-maleimido) caproyl group. 
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TLR7a are typically based on a guanidine, purine, imidazoquinolines or 
benzonapthyridine scaffolds (Scheme 1) (110-115). In our studies we employed a 
guanidine analogue bearing a spacer with an N-hydroxysuccinimidyl ester for 
conjugation to the protein. This requested the development of a coupling strategy 
for the meningococcal antigen that would preserve the amine group of the TLR7a, 
which is fundamental for the activity of the small molecule. We have recently 
shown that two different carbohydrate haptens can be conjugated to the same 
molecule of carrier protein by means of active ester chemistry and thiol-maleimide 
addition as orthogonal reactions (132). CRM197 was used as protein carrier, since it 
is the component of a number of approved glycoconjugate vaccines (131). This 
protein possesses 39 lysine residues, of which 19 are known to be sufficiently 
available conjugation and 6 are highly exposed on the protein surface (100,134-
137). 
Scheme 1| Conjugation of TLR7a to CRMemcs. 
 
To apply a similar strategy we first inserted maleimide groups onto CRM197 by 
reaction of the protein with the commercial EMCS linker. An incorporation of 6.5 
maleimides was found by MALDI TOF MS analysis of the modified protein. After 
a second condensation with the NHS ester of the TLR7a, the small molecule was 
inserted into the protein at a level of 6.6 mol/mol of protein, as estimated by MS 
analysis (Scheme 1). It is worth of note that, due to the lipophilic nature of the 
TLR7a we employed, insertion of higher loadings was not achievable due to protein 
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aggregation. In addition this would imply insertion of a lower number of 
maleimides, rendering more challenging the incorporation of the MenC ligand. The 
meningococcal oligomers for condensation with CRMemcs-TLR7a conjugate were 
prepared by reaction of the known MenCsidea (sidea = di-N-hydroxysuccinimidyl) 
active ester  6  with 2-Mercaptoethylamine-2'-thiopyridine to give the oligomer  7  
(Scheme 2) (109). After removal of thiopyridone by treatment with TCEP, the sugar 
hapten  8  bearing the sulfhydryl groups was incubated with CRMemcs-TLR7a  5  
to give addition to the maleimides exposed onto the protein surface. 
 
Scheme 2| Reactions to modify MenC antigens for coupling to the protein. 
 
SDS-page electrophoresis and MALDI TOF MS clearly showed conjugation of the 
MenC antigen to the modified protein (Figure 3a and Figure 3b). An average ratio 
of ten TLR7a molecules was incorporated for each MenC chain in the final product. 
A MenC-CRMemcs conjugate (2), needed as control for the in vivo studies, was 
prepared as control by direct reaction of CRMemcs with MenC-SH, as previously 
reported. A second control (3) was prepared by reaction of MenCsidea with 
CRM197 to compare our novel construct to a well-known glycoconjugate vaccine. 
The characteristics of the conjugate in comparison to the controls are summarized 
in Table 1. 
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Table 1| Physicochemical characteristics of conjugate (1) and controls.  
Glycoconjugate 
Saccharide
/protein 
(w/w) 
MenC/CRMemcs 
(mol/mol) 
Saccharide/TLR7a/protein 
(w/w/w) 
MenC/TLR7a 
(mol/mol) 
MenC-CRMemcs-TLR7a (1) 0.06 0.6 1:1.1:35 1:10 
MenC-CRMemcs  (2) 0.18 1.8 - - 
MenC-CRMsidea  (3)   0.57 5.6 - - 
a. The sugar content was estimated by HPAEC-PAD;  
b. The number of conjugated small molecules was determined by MALDI TOF MS. 
 
 
Figure 3| Characterization of the formed MenC-CRMemcs-TLR7a conjugate. (a) SDS-page 
electrophoresis of synthetic intermediates and final glycoconjugate in comparison to MenC-
CRMemcs and MenC-CRMsidea; (b) MALDI TOF MS analysis of incorporation of TLR7a (MW of 
TLR7a = 534 Da) on CRMemcs, prepared as reported in ref (132). 
 
In vitro testing  
The capacity of the tricomponent glycoconjugate to engage TLR7 receptor was first 
evaluated in vitro, using human embryonic kidney 293 (HEK293) cells expressing 
luciferase under control of the NF-κB promoter and stably transfected with human 
TLR7 (Figure 4). In this assay, NF-κB activation is measured by monitoring the 
levels of luciferase expression following stimulation of cells with serial dilutions of 
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TLR7 agonists. Resiquimod (R-848) was used as control. The conjugated TLR7a 
showed activation of the receptor comparable to that induced by the unconjugated 
form. Furthermore, the small molecule was an agonist ligand as good as the 
SMIP7,10-phosphonate that was recently shown to behave as excellent adjuvant for 
vaccine formulation when adsorbed on AlumOH (115). This experiment indicated 
that conjugation was not impacting the activity of the TLR7a molecule when 
covalently linked to CRM197 in presence of the carbohydrate hapten. 
 
Figure 4| Activation of TLR7 reporter cell line by different MenC-TLR7a constructs. 25000 TLR7-
HEK293 cells/well were stimulated with 0.0001–10 µM (5-fold steps) of TLR7 agonists. After 6 h, 
luciferase expression was measured and expressed as fold-induction compared to cells incubated 
with PBS+1% DMSO and plotted as averages of duplicates with standard deviations.  
 
In vivo immunological evaluation  
The effect of conjugation of TLR7a to MenC-CRM197 was evaluated by i.m. 
immunization of groups of ten BALB/c mice with two 0.5 µg carbohydrate-based 
doses of vaccine, 2 weeks apart, corresponding to the administration of 0.5 µg of 
TLR7a. The constructs was compared to the conjugate MenC-CRMemcs prepared 
with the same conjugation chemistry and a low saccharide/protein molar ratio, co-
delivered with the same amount of TLR7a. The MenC-CRMsidea, prepared by the 
active ester chemistry and with a higher saccharide/protein molar ratio, was used as 
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control to study the effect of the conjugation chemistry and different level of sugar 
incorporation compared to MenC-CRMemcs. Co-administration of MenC-
CRMsidea with a standard dose (5 µg) of SMIP7,10 adsorbed onto AlumOH was 
the benchmark (115). PBS was the negative control. While anti carbohydrate IgG 
titers measured after the first dose were very low, high levels of anti MenC IgG 
were measured following the boost (Figure 5a). The MenC-CRMemcs-TLR7a 
conjugate elicited IgG titers significantly higher that MenC-CRMemcs or its 
physical mixture with the unconjugated form. The immune response induced by the 
tricomponent vaccine was also higher than the one given by the MenC-CRMsidea 
control. The adjuvant effect imparted by the conjugated TLR7a was remarkably 
lower than that achieved by co-administration of MenC-CRMemcs and a ten-fold 
higher dose (5 µg) of SMIP7,10/AlumOH. This suggests that a threshold level of 
TLR7a accumulation is needed to observe an optimal adjuvant effect. 
When a commonly used dose of AlumOH (200 μg) was mixed to the formulation of 
MenC-CRMemcs-TLR7a conjugate no additive effect was observed in the anti 
MenC IgG levels (Figure 5b). The anti-carbohydrate IgG titers were increased for 
the groups immunized with MenC-CRMemcs alone or with TLR7a, and with 
MenC-CRMsidea, indicating that the adjuvant effect of the TLR7a was 
overwhelmed by the presence of AlumOH. The additive effect of the small 
molecule and AlumOH was only detectable in the group immunized with 5 µg of 
SMIP7,10/AlumOH (Figure 5b), further proving that absorption of the 
phosphonate-small molecule onto AlumOH is needed to enhance of the adjuvant 
activity of the TLR7a.  
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Figure 5| (a) Systemic humoral responses to i.m. administration of MenC-CRMemcs alone, 
conjugated or physically mixed with TLR7a. MenC-CRMsidea+SMIP7,10/AlumOH were the 
controls. MenC-specific IgG titers were analyzed after the second immunization. Intergroup 
comparison was assessed using the Mann-Whitney statistical assay. Medians of MenC-specific IgG 
titers for i.m. immunizations are reported. pValues: MenC-CRMemcs vs. MenC-CRMsidea (p 0.14), 
MenC-CRMemcs+TLR7a vs. MenC-CRMemcs-TLR7a (p 0.003), MenC-CRMemcs-TLR7a vs. MenC-
CRMsidea (p 0.002), MenC-CRMsidea vs. MenC-CRMsidea+SMIP7,10/AlumOH (p 0.0002).  
(b) Systemic humoral responses to i.m. administration of same samples reported in Fig. 4a in 
mixture with AlumOH. MenC-specific IgG titers were analyzed after the second immunization. 
Intergroup comparison was assessed using the Mann-Whitney statistical assay. Medians of MenC-
specific IgG titers for i.m. immunizations are reported. pValues: MenC-CRMemcs+AlumOH vs. 
MenC-CRMsidea+AlumOH (p 0.002), MenC-CRMsidea+TLR7a+AlumOH vs. MenC-CRMemcs-
TLR7a+AlumOH (p 0.065), MenC-CRMemcs-TLR7a+ AlumOH vs. MenC-CRMsidea+ AlumOH  (p 
0.19),  MenC-CRMsidea+ AlumOH  vs. MenC-CRMsidea+ SMIP7,10/AlumOH  (p 0.0002). 
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The predominance of Th1 and Th2 T helper cell subsets is known to result in 
distinct patterns of cytokine secretion, and therefore response to bacterial infections. 
TLR ligands can shift this balance to a higher IgG2a production (138). An increase 
of this isotype levels with Th1-biased response has been associated to the protection 
conferred by different vaccines (139-140). To determine the impact of the 
conjugated TLR7 ligand on the Th1/Th2 balance, the levels of antibody subclasses 
were analyzed by ELISA (Table 2). The co-administration of TRL7 ligand resulted 
in augmented amount of both IgG1 and IgG2a levels, with a stronger effect on the 
latter isotype. The highest level of IgG isotypes were measured for the group 
immunized with MenC-CRMsidea in mixture with SMIP7,10/AlumOH. 
Importantly, the level of the IgG2a was more remarkably increased when TLR7a 
was conjugated to MenC-CRMemcs, as it can be seen from the IgG1/IgG2a ratio in 
Figure 6. This suggests that covalent linkage of the TLR7a is important to 
determine a shift to a Th1 type response. By contrast, when AlumOH was used in 
the formulations, the response was characterized by a prevalence of IgG1 with 
respect to IgG2a also for the tricomponent MenC-CRMemcs-TLR7a vaccine, 
indicating a Th2 driven response which is typical of AlumOH formulated antigens 
(141). 
 
Table 2| Anti-MenC IgG1 and IgG2a median titers  
a.    Medians with interquartile range (IQR); 
b. pValues: IgG1 MenC-CRMemcs-TLR7a vs MenC-CRMsidea + SMIP7,10 p = 0.0002, IgG2a: 
MenC-CRMemcs-TLR7a vs MenC-CRMsidea + SMIP7,10 p = 0.0002. 
 
 
IgG1 
Median (IQR)
a 
IgG2a 
Median (IQR)
a 
MenC-CRMemcs 2 (2-14) 2 (2-2) 
MenC-CRMemcs + TLR7a 27 (2-175) 2 (2-49) 
MenC-CRMemcs-TLR7a
 
188 (144-228) 280 (254-356) 
MenC-CRMsidea 24 (2-119) 31 (2-67) 
MenC-CRMsidea + SMIP7,10
b
 2110 64-2326) 983 (81-1063) 
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Figure 6| IgG1/IgG2a ratio of anti MenC IgG titers (shown in Table 2) elicited by i.m. 
administration of MenC-CRMemcs alone, conjugated or physically mixed with TLR7a, after the first 
boost. MenC-CRMsidea alone and adjuvanted with SMIP7,10/AlumOH was used as control.  
 
The functionality of the elicited murine sera in the first immunization schedule 
(Figure 5a) was assessed by rabbit complement serum bactericidal (rSBA), a model 
that is considered a surrogate of protection for meningococcal antigens (Table 3) 
(104-105). In agreement with the total IgG titers and the increment of IgG2a 
subclass production, a significant increase of bactericidal activity was measured 
when the TLR7a was conjugated to MenC-CRMemcs in comparison to the use of 
the plain MenC-CRMemcs conjugate or its physical mixture with the TLR7a.  
Murine sera from the control MenC-CRMsidea were endowed with higher 
bactericidal activity than MenC-CRMemcs, likely, as result of the higher 
saccharide/protein ratio. This is a parameter which is known to affect the 
immunological activity of glycoconjugate vaccines. The reduced saccharide/protein 
ratio in the tricomponent vaccine, therefore, acts in opposition to the adjuvant effect 
of the TLR7a. The adjuvant effect achieved by conjugation of the small molecule 
was 8-fold inferior to the administration of MenC-CRMsidea and a standard dose of 
SMIP7,10 adsorbed on AlumOH. This is due to the combination of the higher level 
of carbohydrate incorporation of MenC-CRMsidea in combination with the use of a 
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10-fold higher dose of small immunopotentiating molecule/AlumOH in respect to 
conjugation to MenC-CRMemcs. 
Table 3| rSBA titers (MenC C11 strain) measured after the boost  
 
Va  ine 
rSBA titer 
MenC - C11strain 
PBS <16 
MenC-CRMemcs 256 
MenC-CRMemcs +  TLR7a 512 
MenC-CRMemcs-TLR7a 8192 
MenC-CRMsidea 2048 
MenC-CRMsidea + SMIP7,10/AlumOH >65536 
 
 
Conclusions 
TLR7as have emerged as important targets to develop novel adjuvants for 
vaccination. Conjugation of a small immunopotentiator molecule could vehicle the 
ligand to the receptor, localize its action and reduce toxicity. We designed a 
tricomponent anti serogroup C Neisseria meningitidis glycoconjugate vaccine 
composed of MenC oligosaccharide antigens covalently linked to the carrier protein 
CRM197, to which a TLR7a has been in turn conjugated. The assembly of this 
complex construct required the development of a synthetic strategy for orthogonal 
coupling of two different ligands to the same protein molecule. The construct was 
first evaluated in vitro demonstrating that the presence of the oligosaccharides was 
not impairing the interaction of the TLR7a with the receptor. Next, the 
tricomponent vaccine was used to immunize mice in order to determine the effect of 
the adjuvant conjugation in comparison to the co-administration of the conjugate 
and the TLR7a. The influence of the conjugation chemistry and 
carbohydrate/protein molar ratio in the controls was taken into consideration. Co-
administration of a small molecule-phosphonate adsorbed on AlumOH, previously 
reported to confer a strong adjuvant effect towards protein antigens, was used a 
benchmark. Our results unambiguously indicated that conjugation of the TLR7a 
increased the anti-carbohydrate response. This effect was less pronounced than the 
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co-administration of a commercial glycoconjugate with a standard dose of SMIP-
phosphonate adsorbed on AlumOH. The reduction of sugar incorporation which is 
needed for the conjugation of the TLR7a lessens the anti-carbohydrate response, 
and is therefore a parameter which counteracts the enhancement of the immune 
response produced by the adjuvant conjugation. An additive effect of the 
conjugable form of TLR7a and AlumOH was not achieved when the small 
molecule was administered either coupled or physically mixed with the 
glyconjugate. On the contrary, it was manifested when a 10-fold higher dose of 
TLR7a was adsorbed onto the inorganic salt via a phosphonate group. This 
indicated that a threshold amount of TLR7a adsorbed onto AlumOH was necessary 
to further potentiate its adjuvant effect. Absorption on AlumOH offers a greater 
flexibility in the administered dose of TLR7a when compared to the adjuvant 
conjugation to the vaccine antigen. However, insoluble salts of aluminum such as 
AlumOH are known to be reactogenic and not usable for transdermal routes (29). 
The skin is an attractive route for delivery of vaccines since it contains a number of 
immunocompetent cells and is accessible without the use of needles and syringes 
(142). Transcutaneous delivery of small-molecule drugs and skin-permeable 
vaccine adjuvants, for example through microneedle patches, has been shown the 
key to modulate the duration and of the type of immunogenic response to vaccine 
antigens administered by this alternative route (143).  Hence, conjugation of the 
small immunopotentiator molecules to glycoconjugates could be particularly 
beneficial for the development of vaccination via skin delivery. We expect that our 
findings will pave the ground for the rational design of improved adjuvanted 
glycoconjugate vaccines and aid establishing novel and safer vaccination routes. 
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Supplementary data  
 TLR7a conjugation to MenC polysaccharide 
Introduction 
Here are reported the results obtained for the conjugation of TLR7 agonist to the 
polysaccharide chain of anti-meningococcal serogroup C glycoconjugate vaccine as 
a strategy to enhance the anti-carbohydrate immune response. This covalent linkage 
could transport the ligand to the receptor, promote its intracellular accumulation and 
favor the receptor activation following the same receptor targeting concept already 
discussed before. 
 
 
 
 
 
 
 
 
Figure 7| Glycoconjugates prepared for evaluating the effect of covalently linked TLR7a to 
MenC; emcs = N-(ε-maleimido)caproyl group. 
 
After developing a synthetic approach for the preparation of the tricomponent 
TLR7a-MenC-CRMemcs conjugate (9), the construct was evaluated in vivo for the 
impact of the adjuvant conjugation in the anti-carbohydrate immune response by 
comparison to the MenC-CRMemcs conjugate (2), prepared through the same 
conjugation chemistry and co-administered with the unconjugated TLR7a. A 
commercialized anti-MenC glycoconjugate (3) was used as a further control to 
determine the influence of the coupling approach and level of carbohydrate 
incorporation on the anti-MenC immune response. In the animal studies, co-
TLR7a-MenC-CRMemcs (9) 
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administration of MenC glycoconjugate (3) and a small molecule-phosphonate 
adsorbed on AlumOH, was used a benchmark.  
 
Materials and Methods 
Conjugation of TLR7a to MenC 
The oligosaccharide (7) was oxidized with NaIO4 (3 equiv) in 10 mM NaPi pH 7 at 
10 mg/ml sugar based concentration. After stirring at ambient temperature for 3 h, 
the mixture was purified using a G25 Sephadex column. Fractions containing the 
sugar were combined and concentrated. The sugar content was estimated by sialic 
acid assay. The oligomer (10 mmol) was dissolved in 500 ul of NaOAc 100 mM 
containing 3.3 mg of NH4OAc and then 0.5 mg of NaCNBH3 was added. After 
incubation for 48 h at 37°C, the crude mixture was purified using a G25 Sephadex 
column, eluting with 20 mM NaCl. Combined fractions containing the oligomer 
were quantified by sialic acid assay and concentrated. The residues were dissolved 
in DMSO-H20 9:1, then TLR7a (5 equiv) and trimethylamine (20 equiv) were 
added. The mixture was stirred overnight at room temperature, then again purified 
by size exclusion chromatography. Conjugation was carried out after treatment with 
TCEP as described for compound (8). 
Immunization study 
For in vivo study, groups of ten 6-week-old female BALB/c mice were immunized 
by intramuscular injection (i.m.) of 0.5 μg/mouse carbohydrate-based dose of 
glycoconjugates on days 1 and 28. TLR7a was used as immunopotentiator at a dose 
of 0.05 μg/mouse, either conjugated or co-delivered with compound    . 
Coadministration of glycoconjugate  3  and SMIP7,10 (5 μg) adsorbed on AlumOH 
was the positive control. Serum samples were collected on days 0, 14 and 42 and 
analyzed by ELISA for their anti-MenC IgG levels. 
Determination of anti-MenC antibody titers by ELISA 
See above manuscript 
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Results and Discussion 
In vivo immunological evaluation  
The effect of conjugation of TLR7a to MenC-CRM197 was evaluated by i.m. 
immunization of groups of 10 BALB/c mice with two 0.5 µg carbohydrate-based 
doses of vaccine, 2 weeks apart, corresponding to the administration of 0.05 µg of 
TLR7a. The constructs were compared to the conjugate MenC-CRMemcs prepared 
with the same conjugation chemistry and a low saccharide/protein molar ratio, co-
delivered with the same amount of TLR7a. The MenC-CRMsidea, prepared by the 
active ester chemistry and with a higher saccharide/protein molar ratio, was used as 
a control to study the effect of the conjugation chemistry and different levels of 
sugar incorporation compared to MenC-CRMemcs. Co-administration of MenC-
CRMsidea with a standard dose (5 µg) of SMIP7,10 adsorbed onto AlumOH was 
the benchmark (115). PBS was the negative control. While the MenC-CRMemcs-
TLR7a conjugate elicited IgG titers significantly higher than MenC-CRMemcs or 
its physical mixture with the unconjugated form as previously described, no 
adjuvant effect is shown when TLR7a is conjugated to the polysaccharide in the 
MenC-CRM197 glycoconjugate (Figure 8). The immune response induced by the 
tricomponent vaccine was also lower than the one given by the MenC-CRMsidea 
and MenC-CRMemcs controls. These results are probably the consequence of the 
very low amount of TLR7a that can be delivered when conjugated to MenC 
polysaccharide, approximately ten-fold lower than the TLR7a amount delivered 
when conjugated to CRM197 carrier. The adjuvant effect imparted by the conjugated 
TLR7a was remarkably lower than that achieved by the co-administration of MenC-
CRMemcs with a hundred time higher dose (5 µg) of SMIP7,10/AlumOH.   
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Figure 8| Systemic humoral responses to i.m. administration of MenC-CRMemcs alone, conjugated 
or physically mixed with TLR7a. MenC-CRMsidea+SMIP7,10/AlumOH was the control. MenC-
specific IgG titers were analyzed after the second immunization. Intergroup comparison was 
assessed using the Mann-Whitney statistical assay. Medians of MenC-specific IgG titers for i.m. 
immunizations are reported. pValues: MenC-CRMemcs vs. MenC-CRMsidea (p 0,2239), MenC-
CRMemcs+TLR7a vs. MenC-CRMemcs-TLR7a (p 0,0002), MenC-CRMemcs vs MenC-CRMemcs-
TLR7a (p 0,0002), MenC-CRMsidea vs. MenC-CRMsidea+SMIP7,10/AlumOH (p 0,0002).  
 
Conclusions 
A tricomponent anti serogroup C Neisseria meningitidis glycoconjugate vaccine, 
composed of TLR7a conjugated to MenC oligosaccharide antigen covalently linked 
to the carrier protein CRM197, was designed. The tricomponent vaccine was used to 
immunize mice in order to determine the effect of the adjuvant conjugation in 
comparison to the co-administration of the TLR7a. Co-administration of a small 
molecule-phosphonate adsorbed on AlumOH was used as benchmark. The obtained 
results indicate that conjugation of TLR7a to MenC polysaccharide has a negative 
impact on the recognition of MenC polysaccharide antigen and consequently a 
reduction of the anti-carbohydrate response is observed. Moreover the TLR7a 
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amount conjugated to MenC polysaccharide, with this chemical approach, is too 
low to appreciate an adjuvant effect in comparison with the dose of small molecule 
adsorbed onto the inorganic salt via a phosphonate group. The same formulations 
were also tested in combination with AlumOH (200 μg/dose) but no differences 
were observed across the groups indicating that the presence of AlumOH obscures 
all others immune responses. 
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Chapter 4 
Conjugation of a short β-glucan chain, as Dectin-
1 agonist, to the detoxified diphtheria toxin, 
(CRM197), as model antigen, to enhance the 
immune response after intradermal vaccination 
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Conjugation vs physical mixture     
As previously stated, β-(1-3)-glucans are good activators of the innate immune 
response by interaction with the C-type lectin-like Dectin-1 receptor (60-61). In 
chapter 2 it was shown that the absence of adjuvant effect when the β-glucan 
hexasaccharide was delivered in physical mixture or conjugated with the 
Meningococcal C glycoconjugate vaccine. In this study the conjugation of β-glucan 
hexasaccharide to the CRM197 model antigen is proposed as strategy to test the 
capability to enhance the immune response toward a protein model antigen in 
comparison to the previously presented glycoconjugate model antigen. The 
obtained findings are organized in the following manuscript published on Molecular 
Pharmaceutics. 
 
 
Graphical abstract  
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Abstract 
The potential benefits of skin delivery of vaccines derive from the presence of a 
densely connected network of antigen presenting cells in the skin layer, most 
significantly represented by Langerhans cells and dermal dendritic cells. Targeting 
these cells by adjuvant conjugated to an antigen should result in enhanced 
immunogenicity of a vaccine. Since one of the most widely used adjuvants is an 
insoluble salt of aluminium (aluminum hydroxide) which cannot be used for skin 
delivery due to reactogenicity, we focused our attention on agonists of receptors 
present on skin dendritic cells, including the Dectin-1 receptor. β-(1-3)-glucans, 
which are the most abundant components of the fungal surface, are known to 
activate the innate immune response by interaction with the C-type lectin-like 
Dectin-1 receptor. In this work we identified by rational design a well-defined 
synthetic β-(1-3) glucan hexasaccharide as a Dectin-1 agonist and chemically 
conjugated it to the genetically detoxified diphtheria toxin (CRM197) protein 
antigen, as a means to increase the binding to Dectin-1 receptor and to target to skin 
dendritic cells. We demonstrated that the in vitro activation of the receptor was 
significantly impacted by the presentation of the glucan on the protein carrier. In 
vivo results in mice showed that the conjugation of the synthetic β-(1-3) glucan 
when delivered intradermally resulted in higher antibody titers in comparison to 
intramuscular (i.m.) immunization, and was not different from subcutaneous (s.c.) 
delivery. These findings suggest that weak receptor binders can be turned into more 
potent agonists by the multivalent presentation of many ligands covalently 
conjugated to the protein core. Moreover, this approach is particularly valuable to 
increase the immunogenicity of antigens administered via skin delivery. 
 
Keywords: β-glucans, Dectin-1 targeting, glycoconjugates, adjuvant conjugation, 
Skin delivery  
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Introduction 
There are many potential benefits of vaccine skin delivery, which result from the 
presence of a densely connected network of antigen presenting cells (APCs) in the 
skin layer that lies beneath the stratum corneum. This cellular population is most 
significantly represented by Langerhans cells and dermal dendritic cells in the 
epidermis and dermis of the skin (92,144). Using conventional intramuscular 
immunization a large dose of antigen is required to induce a significant immune 
response, due to the relatively sparse population of APCs present in the muscle. 
Hence skin delivery for vaccination offers a promising alternative potentially 
allowing immunization with a lower amount of antigens (145-148). The advantages 
of skin immunization predicted from animal studies have stimulated sufficient 
interest to initiate a numbers of clinical trials (149-152). To further increase the 
systemic and mucosal immune response after skin vaccination a number of 
additional approaches might be used (153). Because the cornified outer layer and 
tight junctions limit vaccine penetration of skin, different devices such as 
microneedles have been used to disrupt the stratum corneum and deposit vaccine in 
the epidermal/dermal space (154). The most promising systems combine barrier 
disruption with the addition of an adjuvant that further increases the vaccine 
potency (75). Adjuvants represent an important component of many modern 
vaccines as they increase the immunogenicity of co-administered antigens such as 
purified, soluble recombinant proteins, which are less immunogenic than whole, 
split, killed or attenuated pathogens. Very few adjuvants are included in licensed 
human vaccines, for example aluminum salts (alum) have been widely used for 
more than 70 years and until recently represented the only adjuvant approved in the 
United States (155). Unfortunately, alum is not useable for skin immunization due 
to the formation of persistent intradermal granulomas at the injection-site (29). 
Adjuvants can enhance the immune responses by “targeting” antigens to receptors 
on dendritic cells. Moreover the physical linking of adjuvant to antigen potentially 
enhances antigen uptake and targets the immunopotentiator properties of adjuvant 
to the antigen-presenting cell (156). Starting from this basic concept, we identified 
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the C-type lectin-like Dectin-1 as an uptake receptor widely expressed by a variety 
of cells present in the skin layers, including monocytes, macrophage, neutrophils, 
Langerhans and dermal dendritic cells, both in humans and the mouse (63,157). 
Hence, the idea was to use a dectin-1 agonists as an adjuvant suitable for 
administration into the skin. The capability of β-(1-3)-glucans, which are the most 
abundant component of the fungal surface, to activate the innate immune response 
by interaction with the Dectin-1 receptor is well documented (61-62). The β-(1-3)-
glucans binding to Dectin-1 induces the phosphorylation of a tyrosine of the 
immunoreceptor tyrosine-based activation motif (ITAM) in the cytoplasmic tail, 
that elicits the secretion of inflammatory cytokines, such as tumor-necrosis factor 
(TNF) and IL-12 (63).  β-glucans activated-DCs are able to stimulate antigen 
specific CD8+ T-cell responses, inducing enhancement of antigen presentation, 
priming and expansion of antigen specific CD8+ T-cells (64-65). To increase the 
adjuvanticity and to better target the dermal dendritic cells, the chemical 
conjugation of β-glucans to the antigen was investigated. Recently it has been 
demonstrated that the covalent linkage of Laminarin (Fig. 1) to a β-mannan-Tetanus 
Toxoid conjugate enhanced the immune response against the mannan antigen in a 
tricomponent vaccine against Candida albicans (66).  The interaction of β-(1-3)-
glucans, which are triplic helix forming polysaccharides, with Dectin-1 has been 
detailed by diverse studies (67-69,158). Linear structures have been found to bind 
best to the receptor in comparison to branched ones (70).
 
The minimal length 
required for interaction is 6-7 repeating units, although the binding becomes tighter 
as the length increases (69-70). Therefore, we were interested in understanding 
whether conjugation of glucan hexamer, which can be synthesized as a well-defined 
pure molecule, to the well-known protein antigen genetically detoxified diphtheria 
toxin (CRM197) could increase the immune response against the protein antigen 
compared to its administered in unconjugated form. CRM197 is widely used as 
protein carrier in many glycoconjugate vaccines
 
(71) and detailed knowledge of the 
chemistry of its conjugation to polysaccharides facilitated its use as an antigen for 
co-administration with the glucan hexamer. The linear and long chain naturally 
extracted Curdlan polysaccharide, considered a potent agonist of Dectin-1 receptor, 
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was used as positive control for comparison. To determine in vitro the optimal 
sugar amount to be loaded onto CRM197, we synthesized a set of β-(1-3) glucan 
hexasaccharides conjugated to CRM197 at different carbohydrate/protein ratios to be 
assayed for Dectin-1 receptor activation. It is known that the binding of weak 
ligands, such as carbohydrates, to specific receptors can be increased by their 
multivalent presentation as glycoclusters or glycodentrimers (159). Also in the case 
of Dectin-1, an important pre-requisite for its signaling has been identified in the 
presentation mode of the β-glucans. For example, an immobilized form of β-(1-3)-
glucans, on the surface of a phagocytosable particle, such as a yeast cell, would 
favor the binding to the receptor (160). These previous findings strengthen our 
choice to conjugate the β-(1-3) glucan hexasaccharide to antigen to better present β-
glucans to the receptor surface.  Next, the properties of the molecule as an adjuvant 
after administration by skin delivery were compared to the intramuscular route 
following in vivo by immunization of mice. Antigen-specific (anti-CRM197,) 
antibody titers induced in the presence of β-glucan, either conjugated or co-
delivered with the antigen, were analyzed and the capability of the short well-
defined β-glucan oligosaccharide as an effective adjuvant for skin delivery was 
evaluated. 
 
 
 
 
 
 
 
Figure 1| Chemical structures of the polysaccharides employed in the study: Curdlan, Laminarin 
and Meningococcal serogroup A (MenA) capsular polysaccharide (71,143,159-163). 
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Materials and methods 
Synthesis of glycoconjugates  
Activated hexasaccharide (2), prepared as previously reported (161) was incubated 
with CRM197 at a molar ratio of 20:1, 30:1 or 50:1, respectively (moles of active 
ester per moles of protein), in 100 mM phosphate buffer at pH 7.0. CRM197 contains 
40 lysine residues, of which 19 are available for glycoconjugation (162). After 
overnight reaction at RT, the conjugate was purified by ammonium sulfate 
precipitation (500 mg/ml). The pellet was dissolved in 10 mM phosphate buffer at 
pH 7.0 and again precipitated with ammonium sulfate (500 mg/ml). After repeating 
this operation twice, the solid was washed twice with a solution of ammonium 
sulfate (500 mg/ml) in 10 mM phosphate buffer at pH 7.0, and finally reconstituted 
with 10 mM phosphate buffer at pH 7.0. The amount of carbohydrate covalently 
linked to the protein was estimated by MALDI TOF MS, using an UltraFlex III 
MALDI-TOF/TOF instrument (Bruker Daltonics) in linear mode and with positive 
ion detection. The samples for analysis were prepared by mixing 2.5 μl of product 
and 2.5 μl of sinapinic acid matrix; 2.5 μl of each mixture was deposited on a 
samples plate, dried at RT for 10 min, and subjected to the spectrometer. The 
formation of glycoconjugates was monitored by SDS-page: samples (5 μg) were 
electrophoresed on a 7% Tris Acetate gel or 4-12% Bis-Tris gel (NuPage, 
Invitrogen) and stained with Coomassie blue. Curdlan polysaccharide, with an 
average polymerization degree (aDP) of 25 repeating units which is typically 
considered agonist of Dectin-1 receptor (positive control), was conjugated to 
CRM197, at an average loading of 9.4 carbohydrate moieties, using a procedure 
reported in literature (143) CRM197-Curdlan conjugate was prepared from 
hydrolyzed Curdlan aDP 25 (143).
 
 
Determination of β-glucan - receptor binding in vitro  
An ELISA assay was performed to test the direct binding of different agonists to 
Dectin-1 receptor. Maxisorp plates (Nunc) were coated overnight at 4°C with 0.2 
μg/well of CRM197-Curdlan (normalized for CRM197 content) in phosphate buffered 
saline (PBS), and blocked for 1 h at 37°C with 200 μl of 1% bovine serum albumin, 
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BSA (Sigma), in PBS. Three different Fc-mDectin-1 (soluble murine Dectin-1 
receptor fused to the C-terminus of human IgG1 Fc domain, InvivoGen) 
concentrations, 1 µg/ml - 0.1 µg/ml - 0.01 µg/ml, were diluted in PBS, 0.1% BSA 
and 0.05% Tween-20 (Sigma) and incubated with 2 μg/ml (sugar content) of each 
analyzed agonist for 10 minutes at RT. 100 µl/well of each mixture (Fc-mDectin-1 
at different concentration plus agonists) were consequently added to the blocked 
ELISA plates and incubated for 2 h at 37°C. The specific binding of agonist to Fc-
mDectin-1 and consequent decrease of coated Curdlan recognition was detected 
with alkaline phosphatase-conjugated goat anti-human IgG (ɣ chain specific, 
SouthernBiotech). The different Fc-mDectin-1 concentrations not pre-incubated 
with agonists were used as negative control of the assay. The optical density was 
read at 405 nm using an ELISA reader.  
 
Cell culture 
RAW-Blue™ cells (InvivoGen), derived from RAW 264.7 macrophages, were used 
as a Dectin-1 reporter cell line as they express high levels of endogenous Dectin-1.  
RAW-Blue™ cells were grown in T-75 culture flasks (Iwaki) in Dulbecco's 
Modified Eagle Medium, DMEM (Gibco), 4.5 g/l glucose, 10% heat-inactivated 
Fetal Bovine Serum, FBS (Gibco) (30 min at 56°C), 100 mg/ml Normocin™ 
(InvivoGen), 2 mM L-glutamine (Gibco), 200 mg/ml Zeocin™ (InvivoGen) 
incubated at 37°C in presence of 0.5% CO2.  
 
Dectin-1 receptor activation: QUANTI-Blue™ assay  
The QUANTI-Blue™ assay allows detection of NF-kB/AP-1 activation, consequent 
to the Dectin-1 agonist binding, by measuring secreted embryonic alkaline 
phosphatase (SEAP) production, using QUANTI-Blue™ (InvivoGen), SEAP 
detection medium. A cell suspension at ~550,000 cells/ml of growth medium was 
prepared. 180 µl of cell suspension plus 20 µl of different Dectin-1 agonists, 
positive (CRM197-Curdlan) and negative controls (CRM197 and CRM197-MenA 
(71,163)) were distributed in a flat-bottom 96-well plate (Corning). The plate was 
incubated at 37°C in a 5% CO2 incubator for 18 h. Subsequently 150 µl of 
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suspended QUANTI-Blue™ plus 50 µl of induced RAW-Blue™ cells supernatant 
were added per well and the plate was incubated at 37°C for 30 min to 6 h. SEAP 
(secreted embryonic alkaline phosphatase) levels were revealed at 620-655 nm 
using a spectrophotometer.  
 
Immunogenicity testing in mice 
Protocols were approved by the Italian Ministry of Health. All mice were housed 
under specific pathogen-free conditions at the Novartis Vaccines Animal Resource 
Center. For both in vivo studies, groups of eight 6-week-old female BALB/c mice 
were immunized. Subcutaneous (s.c.)/intradermal (i.d.) immunization on days 1, 21 
and 35 for the first in vivo study and intramuscular (i.m.)/intradermal (i.d.) 
immunization on days 1 and 21 for the second were conducted. For s.c. 
immunization, 100 µl of CRM197 (4 μg/mouse) conjugated or co-delivered with β-
glucan hexasaccharide (1 μg/mouse) and Curdlan (2,7 μg/mouse) were injected. 
The same antigen/adjuvant dose was delivered intradermally in a 20 µl formulation. 
S.c. immunization with alum hydroxide adjuvanted formulation (0.2 mg/mouse) 
was used as a positive control. Alum hydroxide is an adjuvant widely used for 
carbohydrate-based vaccines (164-165). For i.m. immunization, 100 µl of CRM197 
(50 µl for each muscle - 4 μg/mouse) conjugated or physically mixed with β-glucan 
hexasaccharide (1 μg/mouse) was injected. The same antigen/adjuvant doses were 
delivered intradermally in 20 µl formulations. I.m. immunization with alum 
hydroxide adjuvanted formulation (0.2 mg/mouse) was used as positive control. 
Serum samples were collected on days 20, 34 and 49 for the first in vivo experiment 
and on days 20 and 34 for the second study and analyzed by ELISA for their anti-
CRM197 IgG levels. 
 
Determination of 𝑪𝑹𝑴𝟏𝟗𝟕-specific antibody titers by ELISA 
Determination of anti-CRM197 specific total IgG and subclasses IgG1 and IgG2a 
titers was performed by ELISA using individual serum samples. Maxisorp plates 
(Nunc) were coated overnight at +4°C with 0.2 μg/well of CRM197 in PBS, and 
blocked for 1 h at 37°C with 200 μl of 1% BSA (Sigma), in PBS. For the IgG 
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ELISA assay, serum samples were initially diluted in PBS, 0.1% BSA and 0.05% 
Tween-20 (Sigma), transferred into coated and blocked plates and serially diluted. 
Bound CRM197-specific IgG, IgG1 and IgG2a were detected with alkaline 
phosphatase-conjugated goat anti-mouse IgG, IgG1 and IgG2a respectively 
(SouthernBiotech). Antibody titers, normalized respect to the reference serum 
assayed in parallel, were obtained using IrisLab software. GraphPad Prism v.6.04 
(GraphPad Software, La Jolla, CA) was used to graph and analyze data for 
statistical significance. Intergroup comparison was analyzed using the Mann-
Whitney test.  
 
Results 
Synthesis of glycoconjugates with different degrees of glycosylation 
CRM197-Hexasaccharide (CRM197-Hexa) (3), (4), and (5) at different carbohydrate 
loading were prepared as described in Scheme 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1| Preparation of the 𝑪𝑹𝑴𝟏𝟗𝟕-Hexa glycoconjugate at different carbohydrate loading 
(161). 
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As described above three conjugates with carbohydrate: protein ratios of 8.2, 18.2 
and 28.3, respectively, were obtained. The amount of carbohydrates covalently 
linked to the protein was estimated by MALDI TOF MS (Fig. 2 and Table 1).  
 
 
 
 
Figure 2| SDS page gel electrophoresis and MALDI TOF MS spectra of the glucan hexamer 
conjugated to the model protein𝑪𝑹𝑴𝟏𝟗𝟕. 
 
 
Table 1| Characteristics of protein-adjuvant conjugates. 
Compound MW Sugar loading Yield %
d Conjugation 
efficiency %
e 
CRM197-hexa 3 68864 8.2
a 
89 41 
CRM197-hexa 4 80577 18.2
a 
94 62 
CRM197-hexa 5 98662 28.3
a 
81 56 
CRM197-Curdlan nd
 
9.4
b
 nd 31 
CRM197-MenA
c 
nd
 
5.2
b
 nd 20 
a. The sugar loading was determined by MALDI TOF MS. 
b. The amount of conjugated carbohydrate was determined as described in literature (143). 
c. This conjugate was prepared as reported in literature (71,163) 
d. Recovered protein after purification as determined by microBCA. 
e. Mol of linker sugar/mol reacted sugar. 
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Conjugation of Hexasaccharide improves Dectin-1 receptor activation 
A preliminary study was performed to evaluate the in vitro binding of different 
agonists to Dectin1 receptor. First, the specificity of the binding of the constructs 
presenting the β-(1-3) glucans for the Dectin-1 receptor was assessed (Fig. 3A). To 
this end, by a competitive ELISA, the capability of the different biomolecules to 
compete with the binding of the receptor pre-incubated with CRM197-Curdlan to the 
same conjugate coated on the plate was measured. The receptor, either pre-
incubated or not pre-incubated with the conjugated CRM197-Curdlan, was used as 
control. As additional negative control, we used the CRM197 conjugate of 
Meningococcal serogroup A capsular polysaccharide (MenA), that is known not to 
be a Dectin-1 receptor agonist. As expected, CRM197-MenA conjugate did not 
interact with Dectin-1, indicating that β-(1-3) glucans exhibited specific binding to 
the receptor (Fig. 3A). The unconjugated Curdlan was a weaker competitor in 
comparison to the conjugates, while the hexasaccharide showed almost no binding 
to the receptor, similarly to CRM197-MenA.  
 
 
 
Figure 3| Dectin-1 receptor activation. (A) Competition for Dectin-1 receptor between conjugated 
and not conjugated β-glucans pre-incubated with 𝐶𝑅𝑀197-Curdlan on plate coated with the same 
conjugate. The not pre-incubation of the receptor was used as blank test of assay. (B) RAW-Blue™ 
cells treated with the three different 𝐶𝑅𝑀197-Hexa glycoconjugates (3)(4)(5) with different loaded 
sugar chains. 𝐶𝑅𝑀197-Curdlan was the positive control and Hexa (1), 𝐶𝑅𝑀197 and 𝐶𝑅𝑀197-MenA 
were the negative controls. The experiments were run in duplicates. 
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Having ascertained that the conjugated glucans were recognizing the Dectin-1 
receptor specifically, an in vitro test was performed to evaluate the ability of the 
different CRM197-Hexa glycoconjugates (3)(4)(5) to bind Dectin-1 in cells which 
highly express the receptor and activate the intracellular pathway (Fig. 3B). In order 
to test the effect of the different numbers of sugar chains present in each 
glycoconjugate, all biomolecules were analyzed at the same amount of sugar in 
work solution. CRM197 alone and CRM197-MenA glycoconjugate were used as 
negative controls. CRM197-Curdlan, with an average loading of 9.4 carbohydrate 
moieties, was the positive control. As it appeared from the absorbance values at 630 
nm depicted in Fig. 3B, all the glucan conjugates exhibited activation of the Dectin-
1 pathway, while almost no absorbance was associated to the negative controls, 
CRM197 and CRM197-MenA, respectively. This result suggested that conjugated β-
(1-3) glucans are better agonists than the unconjugated counterparts. Therefore, the 
multivalent exposition of the carbohydrate moieties linked to the protein core in 
form of glycoclusters appeared to potentiate the binding to the receptor (159,166) 
The Dectin-1 activation was found to be influenced by two interconnected 
parameters, which are the number of attached sugar moieties and the relative 
distance onto the protein core. When the number of sugar moieties on the protein 
was similar, as in the Curdlan and hexasaccharide conjugates at loading 9.4 and 8.2 
respectively, the product with the longest sugar chain resulted in a better activation. 
On the other hand, the conjugates (4) and (5) with highest sugar density increased 
the SEAP production in comparison to (3), indicating that this was another 
important feature for the receptor activation. Unexpectedly, conjugate (4) resulted 
in a higher SEAP production than (5), suggesting that a too dense distribution of the 
sugars around the core might not be beneficial for the Dectin-1 stimulation. This 
could be due to the irregular distribution of the glycans around the protein core in 
comparison to the use of synthetically defined clusters (167), however this aspect 
was not further explored. Following the main purpose of this work, to investigate 
the adjuvant effect of the conjugated hexasaccharide compared to its unconjugated 
form for skin delivery, CRM197-Hexa conjugate (4) was selected for the in vivo 
studies.  
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Conjugation of the glucan hexasaccharide to the antigen is essential for adjuvant 
effect in vivo 
To evaluate the effect of conjugation of the synthetic β-(1-3) glucan hexamer on its 
ability to adjuvant the anti-protein response, a set of in vivo experiments was 
designed. In the first in vivo study, immune responses induced by conjugated and 
unconjugated hexasaccharide and Curdlan against the protein CRM197 through 
subcutaneously route (s.c.) and intradermal immunization (i.d.) were investigated 
(Figure 4A and 4B). CRM197 adjuvanted with AlumOH was used as positive control 
for the subcutaneous administration only, since this adjuvant cannot be used for 
intradermal delivery
 
(29), and CRM197 alone was the benchmark. Importantly, 
CRM197-Hexa 18.2 and CRM197-Curdlan conjugates induced anti-CRM197 IgG titers 
significantly higher than the CRM197 alone and corresponding formulations of 
CRM197 physically co-delivered with hexamer or Curdlan, independently of the 
route of administration. Thus the conjugation was essential to induce an adjuvant 
effect (Fig. 4B and Table 2). When the subcutaneous route was evaluated (Fig. 4A), 
anti-CRM197 IgGs titers of sera from mice immunized with two doses of CRM197-
Hexa 18.2 or CRM197-Curdlan were comparable to the sera from mice immunized 
with the positive control - AlumOH adjuvanted formulation. After the third 
dose CRM197-Hexa 18.2 was able to further increase anti-CRM197 IgGs titers while 
CRM197 adjuvanted with CRM197-Curdlan and AlumOH seemed to plateau. Thus 
conjugation of the synthetic hexamer induces a higher immune response compared 
to Curdlan.  In contrast, anti-CRM197 IgGs titers of mice immunized with 
unconjugated saccharide mixed with the protein showed no increase in titers 
compared to CRM197 alone (Fig. 4A).  
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Figure 4| Systemic humoral responses to s.c. and i.d. administration of Hexa and Curdlan 
conjugated to or physical mixture with 𝑪𝑹𝑴𝟏𝟗𝟕 protein. 𝐶𝑅𝑀197-specific IgG titers were analyzed 
after first, second and third immunization. Intergroup comparison was analyzed using the Mann-
Whitney statistical assay. Statistically significant differences are summarized in Table 2. (A) 
Medians of 𝐶𝑅𝑀197-specific IgG titers for s.c. immunizations are reported. (B) Medians of 𝐶𝑅𝑀197-
specific IgG titers for i.d. immunizations are reported. 
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Table 2| Comparison of IgG levels, expressed as medians with interquartile range (IQR), of 
groups showing statistically significant differences (p value) in Figure 4. 
a. p values are indicated as follows: * 0.05 ≤  p < 0.01, ** 0.01 ≤ p < 0.001, and *** p < 0.001; ns = 
not significant. 
 
 
Immunization 
Groups 
Post 1 Post 2 Post 3 
median (IQR) pa median (IQR) pa median (IQR) pa 
𝐂𝐑𝐌𝟏𝟗𝟕+Curdlan 
SC 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕-Curdlan 
SC 
2 (2-33) 
vs 
695 (281-1100) 
*** 
57.5 (43-1158) 
vs 
9198 (7517-
26174) 
*** 
1349 (856-8724) 
vs 
7794 (6846-21323) 
* 
𝐂𝐑𝐌𝟏𝟗𝟕+Hexa 18.2 
SC 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕- Hexa 18.2 
SC 
28 (2-28) 
vs 
695 (339-1753) 
*** 
75 (37-108) 
vs 
23037(13055-
47355) 
*** 
1288 (528-2104) 
vs 
74055 (52153-
154580) 
*** 
𝐂𝐑𝐌𝟏𝟗𝟕+Curdlan 
ID 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕-Curdlan 
ID 
2 (2-2) 
vs 
635 (381-1355) 
*** 
2 (2-105) 
vs 
13643 (10212-
16484) 
*** 
2813 (1043-4569) 
vs 
11624 (10476-
12764) 
*** 
𝐂𝐑𝐌𝟏𝟗𝟕+Hexa 18.2 
ID 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕- Hexa 18.2 
ID 
44 (2-92.75) 
vs 
732 (470-1777) 
*** 
2 (2-51.5) 
vs 
15488 (8342-
24319) 
*** 
1068 (483-1456) 
vs 
34832 (24604-
59682) 
*** 
𝐂𝐑𝐌𝟏𝟗𝟕-Curdlan 
SC 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕+ AlumOH 
SC 
695 (281-1100) 
vs 
2446 (1419-
3997) 
* 
9198 (7517-
26174) 
vs 
21680 (17907-
31449) 
ns 
7794 (6846-21323) 
vs 
43195 (29770-
46856) 
*** 
𝐂𝐑𝐌𝟏𝟗𝟕- Hexa 18.2 
SC 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕+ AlumOH 
SC 
695(339-1753) 
vs 
2446 (1419-
3997) 
* 
23037(13055-
47355) 
vs 
21680 (17907-
31449) 
ns 
74055 (52153-
154580) 
vs 
43195 (29770-
46856) 
* 
𝐂𝐑𝐌𝟏𝟗𝟕-Curdlan 
ID 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕+ AlumOH 
SC 
635 (380.5-
1355) 
vs 
2446 (1419-
3997) 
** 
13643 (10212-
16484) 
vs 
21680 (17907-
31449) 
*** 
11624 (10476-
12764) 
vs 
43195 (29770-
46856) 
*** 
𝐂𝐑𝐌𝟏𝟗𝟕- Hexa 18.2 
ID 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕+ AlumOH 
SC 
732 (470-1777) 
vs 
2446 (1419-
3997) 
* 
15488 (8342-
24319) 
vs 
21680 (17907-
31449) 
ns 
34832 (24604-
59682) 
vs 
43195 (29770-
46856) 
ns 
𝐂𝐑𝐌𝟏𝟗𝟕-Hexa 18.2 
SC 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕- Hexa 18.2 
ID 
695 (339-1753) 
vs 
732 (470-1777) 
ns 
23037 (13055-
47355) 
vs 
15488 (8342-
24319) 
ns 
74055 (52153-
154580) 
vs 
34832 (24604-
59682) 
** 
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Following intradermal delivery, the anti-CRM197 IgG titer elicited by CRM197-Hexa 
18.2 was comparable to the positive control (CRM197+AlumOH by s.c. route, Fig. 
4B and Table 2), whereas sera from the CRM197-Curdlan conjugate exhibited anti-
CRM197 IgG titers significantly lower than the positive control (CRM197+AlumOH 
by s.c. route, Fig. 4B and Table 2). This indicated that conjugation of the synthetic 
hexamer, but not Curdlan, provided an adjuvant effect comparable with that of 
AlumOH (subcutaneously administered) for intradermal immunization. This effect 
was in agreement with the in vitro Dectin1 receptor activation assay, which showed 
CRM197-Hexa 18.2 as a stronger activator than CRM197-Curdlan. We can, therefore, 
assume that the Dectin-1 recognition was better affected by the sugar exposition 
around the protein core rather the repetition along the polysaccharide chain. 
Notably, for both the immunization routes (s.c. and i.d.), antibody titers detected 
after the first immunization using a conjugated form of the antigen highlighted a 
quicker on-set of immune response compared to antigen administered alone that 
was not able to induce any response. Moreover independently from the routes of 
immunization, antibody titers detected after two doses using the conjugated forms 
were higher than titers induced after three immunizations using non-adjuvanted 
formulations or physical mixtures of protein-adjuvant (Fig. 4A and Fig. 4B, Table 
2). This result confirmed the capability of the hexamer (1), when conjugated to the 
protein, to exert an adjuvant effect. To further assess this effect and compare the 
intradermal versus the intramuscular route, a second in vivo experiment was 
conducted. CRM197 co-delivered either with the unconjugated hexamer or AlOH 
was used as control. In the first study no relevant increase in the anti-CRM197 
responses could be observed after the second boost with CRM197-Hexa 18.2.  
Therefore, in the second in vivo study, only two immunizations were evaluated. As 
depicted in Figure 5A and 5B, ELISA titers of sera from first and second 
vaccination confirmed that the conjugation of the sugar to the antigen was crucial to 
achieve an adjuvant effect. 
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Figure 5| Systemic humoral responses to i.m. and i.d. administration of Hexa conjugated to or 
physical mixture with 𝑪𝑹𝑴𝟏𝟗𝟕 protein. 𝐶𝑅𝑀197-specific IgG titers were analyzed after first and 
second immunization. Intergroup comparison was analyzed using the Mann-Whitney statistical 
assay. Statistically significant differences are summarized in Table 3. (A) Medians of 𝐶𝑅𝑀197-
specific IgG titers for i.m. immunizations are reported. (B) Medians of 𝐶𝑅𝑀197-specific IgG titers 
for i.d. immunizations are reported.  
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After the first immunization respective titers were comparable to the AlumOH 
adjuvanted formulation (Table 3, p for post 1 sera). After the second immunization, 
anti-CRM197 IgG titers of sera of CRM197-Hexa 18.2 immunized mice both i.m. and 
i.d. were lower in comparison to the AlOH formulated control (Table 3, p post 2 
sera). Interestingly   CRM197-Hexa 18.2 conjugate delivered by i.d. induced 
significantly higher antibody titers when compared to the i.m. route both after the 
first and second immunization. This result confirmed the potential benefit of using 
the synthetic β-(1-3) glucan hexamer as adjuvant for skin delivery.  
 
 
Table 3| Comparison of IgG levels, expressed as medians with interquartile range (IQR), of 
groups showing statistically significant differences in Figure 5. 
a. p values are indicated as follows: * 0.05 ≤  p < 0.01, ** 0.01 ≤  p < 0.001, and *** p < 0.001; ns = not 
significant. 
 
 
Dectin-1 agonist elicits the same IgG subclass 𝑪𝑹𝑴𝟏𝟗𝟕-specific response as Alum 
hydroxide 
To characterize the quality of the immune response, serum samples of the second in 
vivo study were analyzed for anti-CRM197-specific IgG1 and IgG2a titers (168). 
Alum is known to induce a Th2 response, which results in the predominant 
segregation of IgG1 subclass (144). Conjugation of the β-(1-3)-(1-6) glucan 
Laminarin to OVA peptide has also been reported to result in a prominent 
production of IgG1 antibodies (147).  No difference between AlumOH adjuvanted 
formulation and CRM197-Hexa 18.2 was found for either IgG1 or IgG2a subclasses, 
independently of the route of administration (Fig. 6). Interestingly, a prevailing 
Immunization Groups 
Post 1 Post 2 
Median (IQR) pa median (IQR) pa 
𝐂𝐑𝐌𝟏𝟗𝟕- Hexa 18.2 IM 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕+ AlumOH IM 
155 (106-201) 
vs 
609 (113-1610) 
ns 
1804 (752-2246) 
vs 
21069 (15326-24496) 
*** 
𝐂𝐑𝐌𝟏𝟗𝟕- Hexa 18.2 ID 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕+ AlumOH IM 
526 (258-717) 
vs 
609 (112.3-1610) 
ns 
10861 (3365-15576) 
vs 
21069 (15326-24496) 
* 
𝐂𝐑𝐌𝟏𝟗𝟕- Hexa 18.2 IM 
vs 
𝐂𝐑𝐌𝟏𝟗𝟕-Hexa 18.2 ID 
155 (105.8-200.5) 
vs 
526 (258-717) 
** 
1804 (752-2246) 
vs 
10861 (3365-15576) 
** 
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IgG1 production was found both for Alum and the conjugated glucan hexamer, in 
agreement with what observed for peptide-bound Laminarin (147). Therefore, 
conjugation of the Dectin-1 agonist appeared to enhance the immune response in 
terms of raised IgG levels, while no shift in the Th1/Th2 balance was observed. 
Unconjugated Curdlan-like polysaccharides have been demonstrated to be capable 
of inducing Th17 activity (169).
 
Whether this type of immune response could be 
also evoked by conjugated Curdlan was not explored in the present study, however 
this point may merit further investigation. 
 
 
 
 
 
 
 
 
 
 
Figure 6| CRM197-Hexa 18.2 glycoconjugate elicits both IgG1 and IgG2a. Post 2 CRM197-specific 
IgG1 and IgG2a titers of mice sera reported in figure 5 are reported. Mean titers with standard 
deviations bars are reported. 
 
Discussion 
Different routes for administration of vaccine antigens have been proposed on many 
occasions (170).
 
Intranasal administration, for example, has been shown to 
represent a viable alternative to classic administration routes, particularly when 
mucosal immunity needs to be stimulated (171). However, safety concerns have 
been reported for some intranasal vaccines, possibly as a consequence of the 
redirection of antigens and/or adjuvants to the central nervous system through the 
olfactory epithelium (172-173). In the present study, Dectin-1 agonists were 
investigated as potent adjuvants for skin delivery of protein antigens.  Since 
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Langerhans cells highly express the Dectin-1 receptor on their surfaces, skin 
delivery should benefit more than the classical routes of administration of the effect 
of β-glucans as immunopotentiators.  By comparison of  three different 
administration routes (s.c., i.d. and i.m.), we observed that conjugation of the 
synthetic β-(1-3) glucan in combination with intradermal delivery resulted in higher 
antibody titers compared to intramuscular and subcutaneous delivery. Our finding 
highlights that covalent linkage of the synthetic agonist to proteins is an approach 
particularly suited for increasing the immunogenicity of antigens administered 
intradermally. This is a relevant benefit since classical alum based adjuvants are not 
suitable for administration by this route (29). Analysis of CRM197-specific IgG 
subclasses indicated that conjugation of the glucan hexamer resulted in a prevailing 
IgG1 production. This outcome is in agreement with recent publications, in which 
cooperation between Dectin-1 and TLR4 induces mainly IgG1 production by mouse 
B-cells (174-175). AlumOH used for intramuscular immunization elicited IgG1 and 
IgG2a subclasses in the same ratio as the conjugated glucan hexamer administered 
intradermally. These results were achieved due to a rational study design that 
allowed us to identify a well-defined synthetic β-(1-3) glucan hexasaccharide as a 
suitable Dectin-1 agonist, that was chemically conjugation to a protein antigen to 
increase binding to the Dectin-1 receptor and targeting to the Dendritic cells (DCs).  
It was previously reported that Laminarin, a heterogeneous and variable 
polysaccharide from algae could be used in a tricomponent glycoconjugate vaccine 
to enhance the immune response against a β-mannan antigen (158). The structural 
requirements of β-glucans for Dectin-1 binding have been thoroughly explored. 
Measurements of competition between oligosaccharides for binding a soluble form 
of Dectin-1 revealed that both branched and linear hexadecasaccharides are capable 
of Dectin-1 receptor binding (158). This finding suggests that linear portions of the 
glucans are recognized by the receptor (158).  In particular, it has been shown using 
a glycan-array that 9 to 10 β-(1-3) repeating units are the minimal requirement for 
efficient receptor binding (67). Glycan-arrays are usually affected by the exposition 
of the sugar on the chip surface. Analysis by titration NMR techniques of a set of 
short β-(1-3)-glucans and Laminarin has revealed that binding to the receptor takes 
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place starting from six repeating units and becomes stronger for longer glucans 
(70). Moreover, it has been observed that short β-(1-3)-glucan oligomers, although 
they are not able to adopt any helical arrangements, are able to increase the ratio of 
granulocytes in peripheral blood, potentiation of phagocytosis and production of 
interleukin-2 after intra-peritoneal injection in murine models (62). Using in vitro 
assays we demonstrated that whilst the short hexamer was unable to efficiently bind 
to the receptor, conjugation dramatically increased binding. This result confirmed 
that the mode of presentation is important for activation of the receptor
 
(160) and, 
most importantly, highlighted that receptor binding  of weak ligands of short length 
can be increased by multivalent presentation. Binding to receptor was found to 
increase for longer and more densely distributed sugars around a protein core. 
However, above a certain threshold, further increases in density had no beneficial 
effect. The optimal carbohydrate-protein ratio to achieve the Dectin-1 activation 
was determined and the selected CRM197 conjugate was utilized in in vivo studies. 
Following immunization of mice, sera were tested to detect CRM197-specific 
antibody titers. Notably, conjugation of the synthetic β-(1-3) glucan hexasaccharide 
to CRM197 exhibited an adjuvant effect, comparable to AlumOH adjuvanted 
formulations, thereby demonstrating that conjugation is fundamental for use of the 
hexasaccharide as an adjuvant. This finding was confirmed by the negligible or very 
limited antibody titers elicited by the hexamer administered in physical mixture 
with the antigen. Importantly, after two doses of the hexasaccharide conjugate, the 
anti-protein immune response was higher than that seen after three doses of the 
antigen-hexasaccharide physical mixture.  Thus, adjuvant-antigen conjugation 
facilitates vaccine dose sparing. Besides Dectin-1, other lectins like the murine 
leukocyte CR3 (CD11b/CD18) have been shown to function as a receptor for β-
glucans, promoting activation of cytotoxic responses against tumor cells. Within the 
scope of the present study, interaction of the conjugated hexamer with other β-
glucan receptors cannot be excluded (176). CRM197 conjugated to Laminarin
 
(177) 
or to synthetic or natural linear β-(1-3) glucans has also been reported to confer 
protection against C. albicans infections (143,177). Specific anti β-glucans 
antibodies have been also found to recognize glycan structures on the surface of 
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Aspergillus fumigatus (178). In the present study we ascertained the induction of 
anti β-glucan IgGs (see SI, Figure 7). Therefore, the short synthetic glucan hexamer 
could behave simultaneously as both antigen and adjuvant to target C. albicans and 
A. fumigatus infections. Considering that glycoconjugate vaccines are some of the 
safest and most effective vaccines for reducing, even eradicating, infectious 
diseases (179), conjugation of well-defined synthetic glucans could represent a 
useful strategy for developing new glycoconjugate vaccines for skin delivery, with 
inherent adjuvant properties. We expect that our findings will open new 
perspectives in the use of well-defined carbohydrates as vaccine adjuvants for 
targeted delivery of protein or polysaccharide antigens to dendritic cells helping to 
establish intradermal delivery as a safe vaccination route.  
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Supplementary data 
 Hexa-specific IgG titers 
Introduction 
In the present study the induction of anti β-glucan IgGs were considered in order to 
evaluate the immunogenity against the hexasaccharide. 
Materials and Methods 
Immunization study 
See above manuscript 
Determination of anti-MenC antibody titers by ELISA 
See above manuscript 
Results and conclusions 
Anti β-glucan IgGs were detected after each immunization for the conjugated 
hexasaccharide. A simultaneous behavior as both antigen and adjuvant can be 
associated to the hexasaccharide. For more details see above manuscript. 
Figure 7| Systemic humoral responses to s.c. and i.d. administration of Hexa conjugated to 
𝑪𝑹𝑴𝟏𝟗𝟕 protein. The immunization dose was based on protein content (4 µg). Hexa-specific IgG 
titers were analyzed after first, second and third immunization. Medians of Hexa-specific IgG titers 
for s.c. and i.d. immunizations are reported. Unconjugated glucan hexamer was used as coating 
reagent. 
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Conclusions  
The current work is aimed at the design, formulation and characterization of novel 
vaccines suitable for intradermal delivery and able to induce earlier onset of 
immune response as well as more potent and longer lasting immune responses 
compared to conventional vaccines. With this purpose, two different model antigens 
were used to evaluate the intradermal route as immunological target for vaccination: 
MenC-CRM197 glycoconjugate and CRM197 protein. Moreover different adjuvants 
were used to potentiate the immune responses to antigens and to modulate the 
immune response towards a desired quality profile. Conjugation of adjuvants to 
model antigens was investigated for potential to increase antigen immune response 
when compared to co-delivery of adjuvants and antigens by simple mixture in 
respective formulations. Chapter 2 described the evaluation of the intradermal 
delivery route for the administration of a glycoconjugate vaccine and the use of 
immunopotentiators to further enhance the immunogenicity and to increase 
bactericidal activity after intradermal delivery. Notably, the intradermal delivery of 
MenC-CRM197 glycoconjugate showed superiority in term of immunogenicity and 
bactericidal titer compared to the intramuscular administration, highlighting the 
power of intradermal route for glycoconjugate vaccine delivery. Moreover, the 
addition of adjuvants, in particular TLR4a, LTK63 and TLR7a, allowed for a 
reduced number of doses administered and to modulate the quality of the immune 
response towards a more beneficial, for the model antigen used, Th1 response. The 
improvement of immunogenicity was not appreciable when CRM197 carrier protein 
was intradermally administered. This finding has specified the rational of choosing 
a glycoconjugate antigen to exploit the intradermal route advantages in term of 
immunogenicity. 
To further investigate the role of adjuvant and to ensure codelivery of 
adjuvant/antigen, the conjugation of TLR7a to the glycoconjugate model antigen 
has been investigated in chapter 3. Of the two different conjugation approaches 
developed, the conjugation of TLR7a to CRM197 carrier protein rresulted the only 
one able to enhance the anti-carbohydrate response. In fact, the conjugation of 
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TLR7a to MenC polysaccharide, has showed a negative impact on MenC 
polysaccharide receptor recognition and consequently a reduction of the anti-
carbohydrate response. These findings have opened the path to the rational design 
of improved adjuvanted glycoconjugate vaccines for intradermal route. 
In order to enhance the immune response toward a protein model antigen in 
comparison to the glycoconjugate model antigen, as described in chapter 2, the 
conjugation of β-glucan hexasaccharide to the CRM197 model antigen was presented 
in chapter 4. The results have demonstrated that receptor activation was 
significantly impacted by the presentation of the glucan conjugated to the protein 
carrier. Considering that glycoconjugate vaccines are some of the safest and most 
effective vaccines for reducing, even eradicating, infectious diseases, the 
conjugation of well-defined synthetic glucans could represent a useful strategy for 
developing new glycoconjugate vaccines for intradermal delivery, with inherent 
adjuvant properties.  
The entire picture of reported findings highligthed the importance of the rational 
combination of antigens and adjuvants to develop stable formulations and efficient 
immune responses considering the pathogen and the route of administration. For 
this reason, the formulation science has been proposed as key element of novel 
vaccine development suitable for intradermal delivery. 
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